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ABBREVIATIONS 
 
GENERAL ABBREVIATIONS 
 
3HSD   3α-hydroxysteroid dehydrogenase enzyme 
3-KSR   3-ketosteroid reductase enzyme 
5α-R   5α-reductase enzyme 
5β-R   5β-reductase enzyme 
17HSD  17β-hydroxysteroid dehydrogenase enzyme 
17-KSR  17-ketosteroid reductase enzyme 
AAS   anabolic–androgenic steroids 
ADME  administration, distribution, metabolism, excretion 
APCI   atmospheric pressure chemical ionization 
API   atmospheric pressure ionization 
cDNA   complementary deoxyribonucleic acid 
EI   electron impact 
ER   endoplasmic reticulum 
ESI   electrospray ionization 
FAB   fast atom bombardment 
GC   gas chromatography 
Glu   glucuronic acid 
HPLC   high-performance liquid chromatography 
IAC   immunoaffinity chromatography 
i.d.   internal diameter 
ISTD   internal standard 
LC   liquid chromatography 
LLE   liquid–liquid extraction 
LPME   liquid-phase microextraction 
m/z   mass-to-charge ratio 
MRM   multiple reaction monitoring 
MS   mass spectrometry 
MS/MS  tandem mass spectrometry 
NMR   nuclear magnetic resonance 
PA   proton affinity 
RP   reversed phase 
SN2   bimolecular nucleophilic substitution 
SPE   solid-phase extraction 
SSI   sonic spray ionization 
TIS   turbo ionspray 
TSI   thermospray ionization 
TMS   trimethylsilyl 
UDPGA  uridine-5’-diphosphoglucuronic acid 
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UGT   uridine diphosphoglucuronosyltransferase 
UV   ultraviolet 
 
 
STEROID GLUCURONIDE ABBREVIATIONS* 
 
3-OHSTG  3’-hydroxystanozolol glucuronide  
5α-1-MEG  1-methyl-5α-androst-1-en-3-one-17β-O-glucuronide 
5α-AG   5α-androstane-3α-ol-17β-O-glucuronide 
5α-DHTG  5α-androstane-3-one-17β-O-glucuronide 
5α-DROSTG  2α-methyl-5α-androstane-17-one-3α-O-glucuronide 
5α-MEG   1-methylen-5α-androstane-17-one-3α-O-glucuronide 
5α-MESM1G  1α-methyl-5α-androstane-17-one-3α-O-glucuronide 
5α-MESM2G  1α-methyl-5α-androstane-17β-ol-3α-O-glucuronide 
5α-MTG  17α-methyl-5α-androstane-17β-ol-3α-O-glucuronide 
5α-NG   5α-estran-17-one-3α-O-glucuronide 
5β-BOLDG  5β-androst-1-en-3-one-17β-O-glucuronide 
5β-EPIMG  17β-methyl-5β-androst-1-ene-17α-ol-3α-O-glucuronide 
5β-LMTG  17α-CD3-5β-androstane-17β-ol-3α-O-glucuronide (internal standard) 
5β-MTG  17α-methyl-5β-androstane-17β-ol-3α-O-glucuronide 
5β-NG   5β-estran-17-one-3α-O-glucuronide 
7α-BOLAG  7α,17α-dimethyl-5β-androstane-17β-ol-3α-O-glucuronide 
7β-CALUG  7β,17α-dimethyl-5β-androstane-17β-ol-3α-O-glucuronide 
AG   5α-androstane-17-one-3α-O-glucuronide; androsterone glucuronide 
ETCG   5β-androstane-17-one-3α-O-glucuronide; etiocholanolone glucuronide 
ETG   4-androsten-3-one-17α-O-glucuronide; epitestosterone glucuronide 
MTG 17α-methyl-4-androsten-3-one-17β-O-glucuronide; methyltestosterone 
glucuronide 
NG   estr-4-en-3-one-17β-O-glucuronide; nandrolone glucuronide 
TG   4-androsten-3-one-17β-O-glucuronide; testosterone glucuronide 
 
 
 
* The abbreviation for the corresponding aglycone is obtained by removing the G for 
glucuronide. 
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ABSTRACT 
 
Anabolic–androgenic steroids (AAS) are testosterone derivatives, widely misused by athletes 
because of their potential enhancing effect on physical performance. Within the human body, 
AAS are transformed by phase-I and phase-II metabolic reactions and most often they are 
excreted in urine as glucuronide-conjugates. Electron impact (EI) and GC–MS based methods 
have conventionally been applied in the analysis of AAS metabolites in urine. The methods 
rely on the detection of hydrolyzed and derivatized steroid aglycons and, for that, laborious 
sample preparation must be carried out. Soft ionization methods, such as electrospray (ESI), 
enable the connection of liquid chromatographic (LC) separation to mass spectrometric (MS) 
detection, and thereby, the direct analysis of non-volatile, bulky, and polar compounds, such 
as the AAS glucuronides. Glucuronide-conjugated AAS standards are required for LC–MS 
method development, but only a few are commercially available. 
 
An enzyme-assisted synthesis was optimized to produce milligrams of glucuronide-
conjugated metabolites of the most widely misused AAS. The uridine 
diphosphoglucuronosyl-transferase (UGT) enzymes that catalyze the glucuronidation reaction 
were obtained from the hepatic microsomal fraction of induced Wistar rats. To allow 
characterization of regio- and stereoselectivity and substrate specificity of UGTs, the 
glucuronidation reaction was additionally examined in vitro with recombinant human UGT 
isoenzymes, as well as with human liver microsomes. After the structural characterization of 
the synthesized substances, the conjugates were utilized in the development of a liquid 
chromatographic–tandem mass spectrometric (LC–MS/MS) method designed for the 
determination of intact AAS glucuronides in enzyme-kinetic assays and in human urine. 
 
Enzyme-assisted synthesis was successfully applicable to the production of stereochemically 
pure AAS glucuronides in amounts sufficient for LC–MS/MS method development. The 
glucuronide-conjugated AAS were recovered in milligram amounts (1.3–6.5 mg), with yields 
(13-78%) highest for steroid substrates with 4-ene-3-one structure.  
 
The only recombinant human isoenzymes showing evidence of regioselectivity were 
UGT1A8, 1A9, and 2B15, which appeared preferentially to catalyze 17β-hydroxyl 
glucuronidation. Most recombinant human UGTs did not exhibit a clear preference for 
conjugation to either the 3α-hydroxyl or the 17β-hydroxyl group. Apparent stereoselectivity 
was detected in the formation of nandrolone metabolites 5α-NG and 5β-NG with most of the 
UGT isoenzymes, but the corresponding isomeric pair of methyltestosterone metabolites, 5α-
MTG and 5β-MTG, did not show the similar behavior, however. The substrate specificities 
were closely similar among the groups of structurally analogous UGTs, although inter-
individual differences were observed in their relative activities. In a comparison of rat and 
human liver preparations and recombinant UGT isoenzymes, the main difference was found 
in the conjugation of methyltestosterone, which was glucuronidated only with the human and 
rat liver microsomal UGTs, from which the induced rat liver UGTs were clearly more active. 
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The optimized LC–ESI-MS/MS method enabled the direct analysis of glucuronide 
conjugates. Two structure-specific product ions from both the analyte and the deuterium-
labeled internal standard were monitored in positive ion ESI-MS/MS, and the structure-
specific fragmentation that occurred allowed differentiation of most of the isobaric AAS 
glucuronides with identical product ion spectra. Chromatographic separation was achieved 
with an end-capped C18 column and ammonium acetate buffered acetonitrile–water gradient. 
The optimized method was applied in metabolic in vitro studies of AAS glucuronides. The 
complex urine matrix samples required more effective sample purification, and for that, a 
liquid-phase microextraction (LPME) method was developed. 
  
Enzyme-assisted synthesis with rat liver microsomal UGTs is a suitable approach to the 
small-scale synthesis of glucuronide-conjugated AAS. Relative to recombinant UGT 
isoenzymes, the activity of glucuronidation is significantly higher with the liver microsomal 
preparations, and these are recommended for future synthesis work. UGT isoenzymes are of 
great importance in the examination of the glucuronidation reaction and in future, selected 
UGT isoenzymes may offer an in vitro model to predict in vivo glucuronidation of xenobiotics 
in drug discovery development. The LPME–LC–ESI-MS/MS method is suitable for the direct 
detection of AAS glucuronides in biological samples, offering detection at 1–5 ng/ml level in 
simple sample matrixes and 2–20 ng/ml for most analytes in urine. Because of the 
interference of endogenous compounds in urine, future method development should be 
focused on enhancement of the specificity and, for that, the main task is the improvement of 
chromatographic separation. 
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1. INTRODUCTION 
 
Anabolic–androgenic steroids (AAS) are widely misused compounds among athletes and, 
despite the ban since 1976, the doping use of these substances continues to be a problem for 
sports authorities. Anabolic effects of AAS include the enhancement of skeletal muscle 
strength and the balancing of catabolic conditions after stress; the androgenic effects, such as 
cardiovascular and hepatic disorders, are mainly considered as side effects. Synthetic AAS are 
testosterone derivatives that are designed to deliver the anabolic effects but not the androgenic 
effects of the endogenous analogue. Despite many attempts to synthesize compounds without 
the androgenic effects, both types of effect remain closely associated with the AAS activity. 
    
Because of their non-polar character, AAS are extensively modified by phase-I and phase-II 
metabolic reactions in the human body prior to their excretion in urine. Phase-I reactions – 
oxidation, hydrolysis, and reduction – introduce new functional groups to the steroid 
structure, which increase the polarity of the parent compound. Often they also serve as sites 
for conjugation in subsequent phase-II reactions. The most common conjugation reaction for 
AAS in the human body is glucuronidation and the main site for the reaction is the liver. 
Glucuronidation is catalyzed by uridine diphosphoglucuronosyltransferases (UGTs), which 
are membrane-bound enzymes of the endoplasmic reticulum (ER). The UGT enzyme family 
has several members with a variety of substrate specificities, which makes them capable of 
conjugating substrates with diverse structures of both endogenous and exogenous origin. 
Through glucuronidation the parent compounds are generally transformed into less toxic 
metabolites. In addition to detoxification, coupling with glucuronic acid moiety increases the 
polarity of the steroid aglycone, leading to easier excretion of metabolites in urine. 
 
In the detection of AAS misuse it is useful to focus on the long-term urinary excreted 
metabolites, most of which are glucuronide-conjugated compounds. At present, the analytical 
methods for glucuronide-conjugated AAS are based on gas chromatographic (GC) separation 
and mass spectrometric (MS) detection of hydrolyzed and derivatized steroid metabolites. 
Although the GC–MS methods are robust and sensitive, sample preparation is time-
consuming and GC–MS sample throughput is relatively low. The development of faster and 
simpler methods based on the direct analysis of steroid conjugates is thus of great interest. 
Relatively new developments in analytical instrumentation, especially soft ionization methods 
such as electrospray (ESI) in mass spectrometry, have enabled the direct analysis of non-
volatile biomolecules. A combination of liquid chromatographic (LC) separation with ESI and 
tandem mass spectrometric (MS/MS) detection provides information on the molecular weight 
and structure of compounds, offering an effective analytical approach to qualitative and 
quantitative analysis of AAS glucuronides.  
 
Reference compounds are needed for the LC–MS/MS method development, but today only a 
few AAS glucuronides are commercially available. In vivo production of the reference 
substances runs into ethical problems, as well as practical problems associated with the 
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isolation of pure metabolites from urine. Chemical syntheses have been published for several 
glucuronide conjugates, but a common difficulty is the formation of a racemic mixture and 
unwanted by-products. An alternative approach to chemical in vitro glucuronide synthesis is 
to catalyze the reaction with UGTs obtained from animal tissues such as rat liver microsomes 
or with individual recombinant UGT isoenzymes. The main advantage of the enzyme-assisted 
synthesis over the chemical synthesis is that the stereospecificity of the enzymes allows 
synthesis of stereo-specifically pure conjugates. 
 
Enzyme-assisted synthesis of glucuronide-conjugated AAS was attempted in this study. Rat 
liver microsomes were the source of the UGT enzymes, which were used to produce 
milligram amounts of AAS glucuronides for concomitant LC–MS/MS method development 
(I). Catalytic activities of human liver microsomes and recombinant human UGT enzymes 
towards AAS metabolites were investigated in detail (II). The analytical part of the study 
focused on the development of an LC–MS/MS method for direct analysis of steroid 
glucuronides in human urine. Traditional sample cleanup procedures of liquid–liquid 
extraction (LLE) and solid-phase extraction were compared with the more recently developed 
liquid-phase microextraction (LPME) (IV). Optimization of the instrumental conditions was 
focused on chromatographic separation and structure-specific MS/MS fragmentation of 
glucuronide-conjugated steroid metabolites (III, IV).   
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2. REVIEW OF THE LITERATURE 
 
2.1 ANABOLIC–ANDROGENIC STEROIDS 
 
Anabolic–androgenic steroids (AAS) are synthetic testosterone derivatives, which are 
designed to maintain the anabolic (beneficial effects) and to minimize the androgenic (side 
effects) activities of the endogenous prototype (Haupt and Rovere, 1984). More than 600 
testosterone analogues have been synthesized, a particularly large number of them during the 
1940s and 1950s. A single hormonal receptor apparently mediates both androgenic as well as 
anabolic actions of testosterone, and the complete separation of these two effects has not yet 
been achieved (Celotti and Negri-Cesi, 1992).  
 
Medical use of AAS was initially intended for the treatment of hypogonadism and catabolic 
states (Kennedy, 1992; Lukas, 1993). There is no question about the capability of AAS to 
promote protein synthesis in skeletal muscles (Lamb, 1984), but owing to weaknesses in 
experimental studies (e.g. limited number of test subjects, dosing, non-uniform test 
environments and short experimental periods), it is not clear whether AAS are actually able to 
improve athletic performance (Wilson and Griffin, 1980; Haupt and Rovere, 1984; Celotti and 
Negri-Cesi, 1992). Although the increase in total body weight following androgen 
administration is indisputable, it is unclear whether this is due to true increase in lean body 
mass or merely to salt and water retention (Kennedy, 1992). Some other benefits claimed for 
AAS use are increased blood volume and hemoglobin concentration (Lamb, 1984), together 
with anticatabolic effects (Wilson and Griffin, 1980; Wu, 1997). The metabolism of the 
various AAS is different, leading to differing patterns of side effects, which can roughly be 
categorized as androgenic, dermatological, hematological and cardiovascular, hepatic, 
psychiatric and neurological, renal, and skeletal and muscular (Wilson and Griffin, 1980; 
Kennedy, 1992; Lukas, 1993; Rockhold, 1993; Huhtaniemi, 1994). 
 
Despite the initial ban of the International Olympic Committee at the Olympic Games 1976 in 
Montreal, AAS still represent a major group of misused compounds in sports. The doping 
analytical methodology is faced with a wide variety of target compounds in diverse 
concentrations, as the non-medical administration of AAS is typically performed either in 
on/off cycles with one steroid (6–12 weeks or more per cycle), by continuous stacking of 
more than one steroid at a time, or in a long-term pyramid program with gradually increased 
dosing of several compounds (Rogol and Yesalis, 1992). 
 
 
2.1.1 AAS structure and nomenclature 
 
As depicted in Figure 1, the steroid structure consists of three six-member rings (A-C) and 
one five-member ring (D), thus forming a bulky and non-polar perhydrocyclopentano-
phenanthrene steroid skeleton. Steroids with 4-ene-3-one structure are planar and rigid, as are 
steroids with 5α-oriented proton. In 5β-orientation the A/B ring juncture is bent, so that, for 
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example, the orientation of the axial substituents is switched to equatorial and vice versa 
(Kirk and Marples, 1995). Various structural modifications of testosterone have been 
designed to bypass the extensive first pass metabolism in the body and so enhance the 
potency, or to delay absorption from the injection site (Kennedy, 1992). These modifications 
have been undertaken by alkylation of the 17α-position (Liao, 1973), which allows oral 
administration of the compound, or by esterification of the 17β-position, leading to a 
compound that can be administered intramuscularly (Wilson and Griffin, 1980). Androgen 
activity can also be modified through ring additions or substitutions, such as addition of the 
pyrazol moiety in stanozolol or C-4 substitution of a chlorine atom in clostebol. 
 
 
 
OH
O
OH
O
CH3
O
O
(CH2)9 CH3
O
OH
H
CH3
N
N
H
OH
O
Cl
1
2
3
75
4 6
8
9
10
11
12
13
14 15
16
17
18
19
A B
C D
A
C
B C
D
E
 
 
Figure 1. Examples of AAS structural modifications. A) Testosterone, B) testosterone undecanoate 
(17β-esterified), C) methyltestosterone (17α-alkylated), D) stanozolol (additional pyrazol ring), and 
E) clostebol (C-4 substitution). 
 
 
 
2.1.2 AAS metabolism in the human body 
 
Several metabolic reactions enhance the excretion of AAS by transforming them into less 
toxic, less active, and/or more polar form. In general, metabolic pathways may be divided into 
phase-I and phase-II reactions, and often the two classes of reactions will occur in parallel for 
a certain compound. The practical goal of the study of AAS metabolism in doping control is 
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to ensure that the monitoring is correctly targeted; for most analytes are transformed in some 
way and are very seldom excreted as the parent compounds (Gower et al., 1995). 
 
Phase-I reactions, often referred to as functionalization reactions, typically modify the parent 
compound via hydrolysis, oxidation, and/or reduction (Gibson and Skett, 1994; Rendic, 
1997). The initial and also rate-limiting step in the metabolism of 4-ene-3-one structured 
steroids (e.g. nandrolone) is the non-reversible reduction of the C-4,5 double bond, which 
leads to an asymmetric center at C-5 (Figure 2). Two isomers will be formed, in a ratio 
depending on the relative catalyzing effects of 5α- and 5β-reductase enzymes (Schänzer, 
1996). As soon as the double bond is reduced, the 3-keto group is transformed, predominantly 
by 3α-hydroxysteroid dehydrogenase (3HSD). In D-ring metabolism, 17β-hydroxysteroid 
dehydrogenase (17HSD) has a strong tendency to form 17-keto metabolites (Gower, 1995). 
Spontaneous 17-epimerization has also been reported for 17α-methyl-17β-hydroxy structured 
steroids, originating in decomposition of the corresponding 17β-sulphate conjugate in urine 
and resulting in an inversion of configuration (Bi and Massé, 1992; Schänzer et al., 1992; 
Gower et al., 1995; Schänzer, 1996). Although phase-I reactions already increase the polarity 
and the excretion of AAS, these modifications are most often preparative stages for reactions 
that expose reactive sites of the analyte structure for the following phase-II, i.e. conjugation 
reactions. For AAS the main phase-II reactions are glucuronidation and sulfation. However, 
for doping control purposes urinary AAS screening is typically performed in free and 
glucuronide fraction, sulfate-conjugated metabolites remaining undetected (Uralets and 
Gillette, 2000). 
O
OH
OH
O
H
OH
O
H
3HSD
17HSD
5α-R 5β-R
3HSD
17HSD
A
B C
 
 
 
Figure 2. Phase-I metabolism of nandrolone (A). Modifications with 5α- and 5β-reductase (5α/β-R), 
3α-hydroxysteroid dehydrogenase (3HSD), and 17β-hydroxysteroid dehydrogenase (17HSD) enzymes 
leading to the formation of 5α-estran-3α-ol-17-one (B) and 5β-estran-3α-ol-17-one (C). 
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2.2 GLUCURONIDATION AND UGT ISOENZYMES      
 
    
Conjugation with glucuronic acid is the major conjugation reaction in all mammals. Various 
functional groups have the potential of reacting with glucuronic acid to form O-, S-, N-, and 
C-glucuronides, which means that a wide variety of compounds are metabolized via the 
glucuronidation pathway (Mulder et al., 1990). Glucuronidation is a bimolecular nucleophilic 
substitution (SN2) reaction, which is catalyzed by uridine diphosphoglucuronosyltransferases 
(UGTs; Enzyme Classification E.C. 2.4.1.17) and uses uridine-5’-diphosphoglucuronic acid 
(UDPGA) as the co-substrate. The reaction leads to the attachment of the polar sugar moiety 
to the steroid structure with the immediate inversion of the configuration to yield a β-
glycosidic bond (Figure 3). As a result, these metabolic reactions in most cases terminate the 
activity of xenobiotics and endobiotics. Some notable exceptions exist (Ritter, 2000); 
morphine-6-O-glucuronide (Paul et al., 1989) and the D-ring glucuronide conjugates of 17β-
hydroxy estrogens, testosterone, and dihydrotestosterone, for example, are more toxic than the 
original compounds (Vore and Slikker, 1985). The main site of glucuronidation is the liver, 
although extra-hepatic glucuronidation has been observed in kidney, intestines, lung, and 
prostate  (Bélanger et al., 1998; Hum et al., 1999; Tukey and Strassburg, 2000).  
 
 
O
COOH
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H
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O
OH
O
P O P O C
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O O
O O
OH
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+ UDP + H2O
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Figure 3. A UGT-catalyzed glucuronidation reaction between 17α-methyl-5β-androstane-3α,17β-diol 
(5β-MT) and uridine-5’-diphosphoglucuronic acid (UDPGA). 
 
 
UGTs are a family of enzymes bound in the membrane of the endoplasmic reticulum, which 
catalyze the glucuronidation of various endogenous and exogenous compounds, including 
steroids (Mackenzie et al., 1997). At least 16 different UGTs, ranging from 526 to 533 amino 
acids in size, are encoded by the human genome. The highly homologous carboxyl terminal is 
suggested to contain the domain critical for catalysis and for binding of UDPGA, whereas the 
amino terminal is responsible for the substrate specificity (Mackenzie, 1990). The expressed 
UGT proteins have been categorized into two families (UGT1 and UGT2) on the basis of the 
protein sequence similarity (Figure 4), which is higher than 38% within a single family 
(Tukey and Strassburg, 2000;2001). According to the sequence homology, the enzyme 
families are further divided into subfamilies (Burchell et al., 1991; Mackenzie et al., 1997). 
The most important enzymes involved in steroid glucuronidation are members of subfamilies 
UGT1A and UGT2B (Hum et al., 1999). 
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Figure 4. Sequence similarity of human UGT isoenzymes (according to Tukey and Strassburg, 2000; 
Lévesque et al., 2001). 
 
 
An earlier approach to the detection of human UGT specificity was the isolation and 
purification of the enzymes from hepatic microsomes by chromatofocusing (Irshaid and 
Tephly, 1986). With the development of cDNA cloning and expression techniques, the 
availability of recombinant isoenzymes has expanded the characterization of enzyme 
activities. Several human UGT proteins have been cloned and studied to characterize steroidal 
substrate specificity of the isoenzymes, the main focus of the research being on the 
glucuronidation of clinically important endogenous steroids, such as testosterone, 5α-
dihydrotestosterone, 5α-androstane-3α,17β-diol, and androsterone (Figure 5). The latter three 
compounds are testosterone metabolites, easily converted to each other in the liver, and their 
glucuronidation has an influence, therefore, on the level of these hydroxysteroids in the body 
(Jin et al., 1997; Bélanger et al., 1998). For example, the level of glucuronide-conjugated 
androgen metabolites in serum has been suggested to correlate with the total pool of 
androgens in men (Labrie et al., 1997).  
 
The data relevant to the activity and specificity of UGT enzymes toward androgens has come 
from several laboratories using different experimental conditions and analytical methods, 
which means that occasionally the data are inconsistent and do not easily support conclusions. 
A rough overview of the role of UGT isoenzymes in human androgen glucuronidation, with 
related references, is nevertheless presented in Table 1. According to earlier investigations, 
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human UGT1 proteins are actively involved in the glucuronidation of steroids, especially of 
the steroids having C18 structure (Hum et al., 1999). In addition, conjugation capability 
toward C19 steroids has been reported for UGT1A3, UGT1A4, UGT1A8, and UGT1A10; 
however, their activities are higher for estrogens and catechol estrogens.  
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B 
C 
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Figure 5. Interrelation of metabolism of A) testosterone, B) 5α-dihydrotestosterone, C) 5α-
androstane-3α,17β-diol, D) androstenedione, E) 5α-androstanedione, and F) androsterone 
(according to Rittmaster et al., 1988). Abbreviations:  5α-R=5α-reductase, 17-KSR=17-ketosteroid 
reductase, 3-KSR=3-ketosteroid reductase. 
 
 
Members of the UGT2B subfamily are well known for their ability to glucuronidate 
hydroxysteroids, showing interesting evidence of the regio- and stereoselective conjugation of 
endogenous androgens and pregnanes (Jin et al., 1997). Isoenzyme UGT2B4 exhibits 
reactivity toward 5α-reduced androgens, e.g. 5α-androstane-3α,17β-diol (5α-A) and 
androsterone (A), although at a significantly lower level than UGT2B7, 2B15, or 2B17 
(Turgeon et al., 2001). UGT2B7, probably the most widely examined isoenzyme with respect 
to androgen glucuronidation, has been found capable of conjugating several endogenous 
hydroxysteroids with 3-hydroxyl and/or 17-hydroxyl structure, and demonstrates more 
efficient glucuronidation of 5α-A than any other human UGT2B isoform (Turgeon et al., 
2001). So far the only member without any reported androgen substrate is UGT2B10. 
Isoenzyme UGT2B11, which is closely similar to UGT2B10, has also been inactive toward 
androsterone and testosterone (Jin et al., 1993; Lévesque et al., 2001), but it has been found 
active toward the 3α-hydroxyl structure of 5α-A (Jin et al., 1997). UGT2B15 is suggested to 
prefer 17β-conjugation, as well as for 5α-androstane compounds over the corresponding 5β-
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structures (Chen et al., 1993; Green et al., 1994). The last two isoenzymes of the UGT2B 
family, UGT2B17 and UGT2B28, have been found capable of glucuronidating several 
endogenous C19 steroids at the hydroxyl group at both 3α- and 17β-position (Beaulieu et al., 
1996; Lévesque et al., 2001).  
 
 
Table 1. UGT isoenzyme tissue distribution and examples of experiments carried out with androgens. 
See nomenclature in Table 3. n.d. = not detected, * = and several other hydroxysteroids.  
Enzyme Tissue distribution Reported androgen substrates References
UGT1A1 Liver, bile ducts, stomach, colon n.d.
King et al. , 1996     
Strassburg et al. , 1998
UGT1A3 Liver, bile ducts, stomach, colon
n.d. (Green et al. , 1998)         
A
Mojarrabi et al. , 1996;     
Green et al. , 1998;              
Gall et al. , 1999
UGT1A4 Liver, bile ducts, colon 5α-A Green et al. , 1996;
UGT1A5 ND n.d. Tukey and Strassburg, 2000
UGT1A6 Liver, bile ducts, stomach, colon, brain n.d. Tukey and Strassburg, 2000
UGT1A7 Esophagus, stomach n.d. Strassburg et al. , 1998        Tukey and Strassburg, 2000
UGT1A8 Esophagus, ileum, jejunum, colon
n.d. (Strassburg et al. , 1998)    
5α-DHT, ET, T 
Strassburg et al ., 1998      
Cheng et al. , 1999
UGT1A9 Liver, colon, kidney n.d. Tukey and Strassburg, 2000
UGT1A10
Esophagus, stomach, 
bile ducts, intestine, 
colon
5α-DHT, A
Strassburg et al. , 1998   
Cheng et al. , 1999          
Tukey and Strassburg, 2000
UGT2B4
Liver, prostate, testis, 
mammary gland, lung, 
kidney
5α-A, A
Hum et al. , 1999      
Lévesque et al ., 2001     
Turgeon et al. , 2001
UGT2B7 Liver, mammary gland, lung, kidney 5α-A, 5α-DHT, A, ET, T, *
Coffman et al. , 1998            
Gall et al. , 1999        
Lévesque et al. , 2001      
Turgeon et al. , 2001
UGT2B10
Liver, prostate, testis, 
mammary gland, lung, 
kidney
n.d.
Jin et al. , 1993                  
Hum et al. , 1999      
Lévesque et al. , 2001
UGT2B11
Liver, prostate, 
mammary gland, lung, 
kidney
n.d.                                           
5α-A (Jin et al., 1997)
Jin et al. , 1993;1997              
Hum et al. , 1999      
Lévesque et al. , 2001
UGT2B15
Liver, prostate, testis, 
mammary gland, lung, 
kidney
5α-A, 5α-DHT, T
Green et al. , 1994           
Hum et al. , 1999      
Lévesque et al. , 2001      
Turgeon et al. , 2001
UGT2B17
Liver, prostate, testis, 
mammary gland, lung, 
kidney
5α-A, 5α-DHT, A, ETCH, T
Beaulieu et al. , 1996         
Hum et al. , 1999        
Lévesque et al. , 2001
UGT2B28 Liver, mammary gland 3α-diol, A, T Lévesque et al. , 2001
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The prevalence of genetic polymorphism has been demonstrated for UGT1A1, 1A6, 1A7, 
2B4, 2B7 and 2B15, although the functional significance has been undisputedly shown only 
for UGT1A1 with conjugation of bilirubin (Miners et al., 2002). With androgens, studies have 
been carried out with two allelic forms of UGT2B7 (H268 and Y268) showing 
glucuronidation for androsterone (3α-hydroxyl) but not for testosterone (17β-hydroxyl), even 
though they both were readily conjugated by human liver microsomes within the same study 
(Gall et al., 1999). The result is in good agreement with that of another study (Coffman et al., 
1998), which also reported the conjugation of androsterone and non-conjugation of 
testosterone with both UGT2B7 isomers. Interestingly, however here they both 
glucuronidated the 17α-hydroxyl group of epitestosterone. The altered catalytic activity of 
mutants has been proposed to be of toxicological significance in general glucuronidation 
(Miners et al., 2002), and the polymorphism has been suggested to offer a plausible 
explanation for some of the observed ethnic differences in steroid hormone profiles and drug 
metabolism (Lampe et al., 2000). These suggestions are still without confirmation, however. 
 
 
2.3 MASS SPECTROMETRY IN THE DETECTION OF ANABOLIC STEROIDS 
 
Spectroscopic methods for the trace analysis (i.e. nano and picomolar concentrations) of 
steroids in biological fluids have been available since the end of the 1960s, gas 
chromatography with packed columns then being the separation method with highest 
resolving power (Jaakonmäki et al., 1967; Horning et al., 1968). In the early 1970s, 
immunoassays were introduced for steroid measurements (Barnard et al., 1995). With the 
later development of labels, detection systems and automation, steroid immunoassay methods 
have become of great importance in routine clinical chemistry. Although thin-layer 
chromatography (TLC) is not applied in human doping control, both TLC and 
radioautographic techniques are successfully used in the detection of radiolabeled steroid 
glucuronides in kinetic studies on AAS (Green et al., 1994; Gall et al., 1999). Immunoassays 
have also been applied as screening methods in doping control of AAS (Catlin et al., 1987). 
Because of the rapid improvement in sensitivity and specificity, as well as in data processing 
systems, mass spectrometric (MS) detection of AAS metabolites has nevertheless replaced 
almost all other methods in doping control laboratories, for both screening and confirmatory 
analysis (Gower et al., 1995). 
 
Analysis of ions as a function of their mass-to-charge ratio (m/z) gives MS its unique power 
in identification, the specificity of the technique often being compared to human fingerprints 
(McLafferty and Lory, 1981), especially when tandem mass spectrometric methods are 
applied (McLafferty, 1981). In MS measurements the compounds pass through two or three 
stages, namely 1) chromatographic separation in the case of a mixture of analytes, 2) 
ionization, and 3) analysis of the produced ions according to their m/z values. There are 
several options for each stage, and the combination of options chosen will depend on the 
analytes, as well as on the requirements for the analysis (e.g. high resolution for accurate mass 
measurements). The significance of chromatographic separation is diminishing with the 
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recent arrival of the high-throughput applications, and the provision of specificity is being 
transferred to the MS analysis. Most often, however, gas chromatography (GC) or liquid 
chromatography (LC) is still applied for the separation of analytes.   
 
 
2.3.1 Gas chromatography–mass spectrometry (GC–MS) 
 
The analysis of AAS metabolites in urine has conventionally been carried out by electron 
impact (EI) and GC–MS based methods for the total fraction of the steroids, i.e. both free and 
conjugated fractions (Figure 6). The first step in the procedure is solid-phase extraction 
(SPE), which may be carried out, for example, with C18 cartridges (Massé et al., 1989) or 
XAD-2 resin (Schänzer and Donike, 1993). This provides the preliminary purification of the 
urine sample by removing salts and polar impurities. An additional purification step, liquid–
liquid extraction (LLE), is often carried out with diethyl ether (Ayotte et al., 1996), pentane, 
or tert.-butyl methyl ether (Schänzer et al., 1996). Specific antibody–antigen binding 
properties of immunoaffinity chromatography (IAC) have also been exploited for the isolation 
of AAS in urine (van Ginkel, 1991), especially in confirmatory analysis (Schänzer et al., 
1996). 
 
The analysis of a conjugate fraction is indirect, since the glucuronide conjugates (G) and 
sulfate-conjugated (S) steroids are hydrolyzed enzymatically (G,S) or chemically (S), or via 
methanolysis (G,S) before further stages of the procedure (Sample and Baezinger, 1989; 
Massé et al., 1989; Tang and Crone, 1989). Non-volatile compounds such as AAS 
metabolites are not amenable to GC separation as such, and the hydrolyzed analytes are most 
often modified to trimethylsilyl (TMS) derivatives (Chambaz and Horning, 1969;Donike and 
Zimmermann, 1980;Donike et al., 1984). Recently, TMS derivatization and GC–MS analysis 
has been applied for the characterization of chemically synthesized intact AAS glucuronides 
to be used as pure reference compounds (Thevis et al., 2001a;b) and for the characterization 
of endogenous androgen glucuronides in human urine (Choi et al., 2000).  
 
In general terms, the GC–MS methods in AAS analysis are sensitive and robust. However, the 
multi-staged procedure is tedious; especially the enzymatic hydrolysis step (Figure 6). 
Moreover, some problems may arise in the hydrolysis step, as the competitive or non-
competitive inhibition of the enzyme may lead to incomplete hydrolysis in urine matrix 
(Bowers and Sanaullah, 1996), and, in certain cases, contaminants in the enzyme preparation 
may lead to the conversion of steroid structures (Messeri et al., 1984). These potential 
problems of GC–MS make the development of alternative methods, such as direct 
measurement of AAS conjugates by LC–MS, highly attractive. 
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2.3.2 Liquid chromatography–mass spectrometry (LC–MS) 
 
The lack of chromophores and fluorophores in AAS glucuronide structures prevents the use 
of UV and fluorescence detectors, the standard detectors in LC. In this respect, the 
development of instrumentation providing interfacing of LC to MS, has opened up broad new 
possibilities for the direct analysis of thermolabile, non-volatile, bulky, and polar compounds, 
such as the AAS glucuronides. By means of LC–MS also the simultaneous detection of the 
total steroid fraction (i.e. free, sulfate- and glucuronide-conjugated AAS) becomes possible. 
Negative ion desorption chemical ionization, by applying ethanolic solution to a Pt wire, was 
applied for underivatized steroid glucuronides as long ago as 1981 (Bruins, 1981). 
Immediately after the introduction of this technique, moving belt (Alcock et al., 1982) and 
fast atom bombardment (Cole et al., 1987; Gaskell, 1988; Tomer and Gross, 1988) were 
presented for the ionization of steroid glucuronides.  
 
 Urine 
Solid-phase extraction Solid-phase extraction 
Conjugates Free steroids 
Enzymatic hydrolysis 
Liquid-phase extraction Liquid-phase extraction 
Derivatization 
Urine 
GC-MS analysis LC-MS analysis of the 
total steroid fraction 
 
Figure 6. Comparison of principles of gas chromatographic–mass spectrometric (GC–MS) and liquid 
chromatographic–mass spectrometric (LC–MS) analysis. 
 
 
The introduction of atmospheric pressure ionization (API) techniques enabled the effective 
breakthrough of LC–MS methods. Atmospheric pressure chemical ionization (APCI; Mück 
and Henion, 1990; Sjöberg and Markides, 1998; Joos and Van Ryckeghem, 1999; Draisci et 
al., 2001), atmospheric pressure photoionization (APPI; Robb et al., 2000), electrospray (ESI; 
Bowers and Sanaullah, 1996; Sanaullah and Bowers, 1996; Bean and Henion, 1997; Draisci et 
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al., 1997; Williams et al., 1999; Borts and Bowers, 2000; Que et al., 2000; Nielen et al., 
2001; Leinonen et al., 2002; Van Poucke and Van Peteghem, 2002), sonic spray (SSI; Jia et 
al., 2001), and thermospray ionization (TSI; Watson et al., 1986; Liberato et al., 1987) have 
been applied in the detection of free as well as glucuronide- and sulfate-conjugated AAS in 
pharmaceutical preparations and biological matrixes.  
 
Electrospray ionization (ESI) has been the method of choice for AAS glucuronides. In ESI the 
ions are transferred from the charged initial droplets to gas phase, either directly by 
evaporation from the small droplets near the Rayleigh limit (Iribarne et al., 1976) or through 
consecutive steps of coulombic fission, which eventually lead to the formation of droplets 
containing only one ion (Schmelzeisen-Redeker et al., 1989) (Figure 7). ESI is characterized 
as a soft ionization process where there is little if any addition of internal energy to the ions 
(Kebarle and Tang 1993). Analytes are typically observed as protonated [M+H]+ or 
deprotonated [M-H]- molecules, in positive or negative ion ESI, respectively, which has been 
demonstrated for AAS glucuronides (Bowers and Sanaullah, 1996; Bean and Henion, 1997; 
Borts and Bowers, 2000). In addition to AAS analysis, ESI-based LC–MS methods have 
become widespread in forensic science and biochemical and pharmaceutical analysis (Henion 
et al., 1993; Maurer, 1998; Niessen, 1999; Bogusz, 2000; Griffiths et al., 2001). 
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Figure 7. Schematic picture of the formation of gas phase ions in electrospray ionization (ESI) 
according to A) ion evaporation theory and B) charge residue theory. 
 
 
Conjugated reference material is needed for the analysis of intact steroid glucuronides by LC–
MS, but for exogenous AAS in particular only a few conjugates are commercially available. 
Several chemical syntheses have been described for steroid glucuronides (Conrow and 
Bernstein, 1971; Chung et al., 1992; Hadd, 1994; Sanaullah and Bowers, 1996; Stachulski 
and Jenkins, 1998; Thevis et al., 2001a;b). These classical syntheses produce AAS 
glucuronides in milligram amounts, but the potential formation of the corresponding α-
anomers and other side-products is a problem, so that further purification is required for the 
isolation of the desired isomer (Conrow and Bernstein, 1971). 
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An alternative to the classical chemical syntheses is the enzymatically driven pathway, using 
tissue preparations or recombinant isoenzymes as the source of the catalyzing UGT enzymes 
for glucuronidation. Given the high specificity of UGTs, the strength of the enzyme-assisted 
synthesis lies in the formation of a stereochemically pure product (Mackenzie et al., 1992). 
Enzymatically driven syntheses have been demonstrated, for example, for the production of 
glucuronide-conjugated androsterone, androstanediol, dihydrotestosterone (Rittmaster et al., 
1989), epitestosterone (Falany and Tephly, 1983), and testosterone (Rao et al., 1976; 
Numazawa et al., 1977). 
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3. AIMS OF THE STUDY 
 
 
• The main goal of the study was to optimize an enzyme-assisted synthesis procedure, 
and to produce milligrams of glucuronide-conjugated metabolites of the most widely 
misused anabolic androgenic steroids (AAS). The syntheses were carried out with 
hepatic UGT enzymes obtained from the microsomal fraction of induced Wistar rats. 
In addition to this larger-scale production of the conjugates, the AAS glucuronidation 
reaction was examined in vitro with a set of 11 recombinant human UGT isoenzymes, 
as well as with human liver microsomes, in order to characterize the potential regio- 
and stereoselectivity and substrate specificity of UGTs.  
 
 
• In the analytical part of the study, the structures of the synthesized substances were 
characterized, and the conjugates were utilized in the development of a liquid 
chromatographic–tandem mass spectrometric (LC–MS/MS) method. LC separation 
and MS detection steps were optimized for the determination of intact AAS 
glucuronides in enzyme-kinetic assays. When the LC–MS/MS method was 
implemented in the analysis of AAS glucuronides in human urine, impurities in the 
samples required the adaptation of a relatively new sample purification and 
concentration method, liquid-phase microextraction (LPME).  
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4. MATERIALS AND METHODS 
 
Only the major experimental features are described in this section. More detailed descriptions 
can be found in the original publications I–IV. 
 
 
4.1 REAGENTS 
 
The detailed list of reagents, solvents, and gases of the study is presented in Table 2. For MS 
work all the glassware was flushed with 5% nitric acid and rinsed with ion-exchanged water 
(Millipore, Milli-Q Plus, France). 
 
Table 2. Solid reagents, solvents, and gases of the study, with their quality and source. 
Reagent Quality Producer Country
Ammonium acetate Pro analysi Merck Germany
Disodium hydrogen phosphate dihydrate Pro analysi Merck Germany
Magnesiumchlorid-6-hydrat Pro analysi Riedel-de Haën Germany
Potassium chloride Pro analysi Riedel-de Haën Germany
Potassium dihydrogen phosphate Pro analysi Merck Germany
Saccharic acid 1,4-lactone Desiccate Sigma MO, USA
Uridine-5’-diphospho-glucuronic acid Disodium salt Sigma MO, USA
Solvent Quality Producer Country
Acetic acid HPLC grade Rathburn Scotland
Acetone-d 6 99.50 % Aldrich WI, USA
Acetonitrile HPLC grade Rathburn Scotland
Dichloromethane HPLC grade Baker The Netherlands
Diethyl ether Analytical grade Riedel-de Haën Germany
Ethyl acetate Pro analysi Merck Germany
Formic acid Analytical grade Riedel-de Haën Germany
Methanol HPLC grade Baker The Netherlands
Methanol-d 4 99.50 % Acros Organics Belgium
n -Octanol Extrapure Merck Germany
2-Octanone Purum Fluka Germany
Pentylacetate Pro analysi Fluka Germany
Perchloric acid Pro analysi Merck Germany
Water Milli-Q Plus Millipore France
Gas Filter system Producer Country
Air CD-2 Atlas Copco Belgium
Nitrogen 75-72 nitrogen 
generator
Whatman MA, USA
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4.2 STEROIDS, STEROID GLUCURONIDES AND URINE SAMPLES 
 
The AAS glucuronides in the study consisted mainly of phase-I modified steroid metabolites, 
but some parent compounds were also included. The structures, nomenclature, and sources of 
the AAS glucuronides and the sources of steroid aglycones used as precursors in enzyme-
assisted syntheses are presented in Table 3. Preliminary LC–MS/MS work was done with 
pure reference compounds, which were spiked in a solvent system consisting of 15 mM 
ammonium acetate in water–acetonitrile (50–50, V/V). For the positive ion mode ionization 
the pH was adjusted to 4.2 with formic acid. Further LC–MS/MS method development was 
performed with spiked urine samples; for these, drug-free male and female pools of spot urine 
samples were obtained as a generous gift from United Laboratories Ltd. (Helsinki, Finland).   
 
For the synthesis of the internal standard 5β-LMTG (17α-CD3-labeled structural analogue of 
5β-MTG), the deuterium-labeled steroid aglycone was synthesized by chemical method 
(Shinohara et al., 1984) and then conjugated via enzyme-assisted reaction identically with 5β-
MTG. The resulting d3-labeled glucuronide conjugate was applied as internal standard in all 
LC–MS/MS experiments. 
 
   
4.3 METHODS 
       
4.3.1 Enzyme-assisted synthesis of steroid glucuronides 
 
Liver microsomes were prepared from Aroclor 1254 induced (a single dose of 500 mg/4.5 ml 
olive oil/body weight) male Wistar rats (n=5) at the Department of Industrial Hygiene and 
Toxicology (Finnish Institute of Occupational Health, Helsinki, Finland) according to a 
previously described procedure (Luukkanen et al., 1997). The treatment of the animals was 
approved by the local ethical committee for animal studies. Specific UGT activity of the 
preparation was not measured, but a commercial BCA protein assay kit (Pierce, IL, USA) was 
used for the determination of protein concentration, which was used to standardize the amount 
of microsomal enzymes in the syntheses (I).  
 
The incubation matrix was 50 mM phosphate buffer (pH 7.4) with 5 mM MgCl2. Because of 
the risk of bond-breaking enzymes in the tissue preparate, constant concentration (5 mM) of 
saccharic acid 1,4-lactone, β-glucuronidase inhibitor was added to the reaction mixture. 
Optimal concentrations of the steroid substrate (aglycone), uridine-5’-diphospho-glucuronic 
acid (UDPGA) and microsomal protein were determined in the small-scale incubations (100 
µl) within the corresponding ranges of 1–1000 µM, 0.5–10 mM, and 0.1–1.75 mg/ml. The 
steroid substrate was dissolved in methanol, the amount of which was 10% of the total 
incubation volume. The reaction was initiated with UDPGA without pre-incubation and 
carried out in water bath of 37°C for 12–15 hours with continuous magnetic stirring. The 
reaction was terminated by transferring the incubation mixture to an ice bath, and enzymatic  
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Table 3. Structures, nomenclature and sources of steroid glucuronides and sources of the steroid 
aglycones used as starting material in enzyme-assisted syntheses. * 17α-CD3-labeled analogue of 5β-
MTG (internal standard); UH University of Helsinki; DSHS Deutsche Sporthochschule, Cologne, 
Germany; NARL National Analytical Reference Laboratory; Pymble, Australia; Steraloids, Wilton, 
NH; where two or more sources are indicated, the sources after the slash (/) are for the steroid 
aglycones. 
 
 
 
Abbreviation Compound Precursor Structure Source
3-OHSTG 3'-hydroxystanozolol glucuronide stanozolol NARL
5α-1-MEG
1-methyl-5α-androst-    
1-en-3-one-                   
17β-O -glucuronide
methenolone UH / DSHS
5α-AG 5α-androstane-3α-ol-17β-O -glucuronide testosterone UH / DSHS
5α-DHTG 5α-androstane-3-one-17β-O -glucuronide testosterone NARL
5α-DROSTG
2α-methyl-5α-
androstane-17-one-       
3α-O -glucuronide
drostanolone NARL
5α-MEG
1-methylen-5α-
androstan-17-one-         
3α-O -glucuronide
methenolone UH / DSHS            NARL
5α-MESM1G
1α-methyl-5α-
androstane-17-one-      
3α-O -glucuronide
mesterolone NARL
5α-MESM2G
1α-methyl-5α-
androstane-17β-ol-      
3α-O -glucuronide
mesterolone NARL
5α-MTG
17α-methyl-5α-
androstane-17β-ol-       
3α-O -glucuronide
mestanolone    
methyltestosterone    
oxymetholone
UH / DSHS; Steraloids   
NARL
5α-NG 5α-estran-17-one-      3α-O -glucuronide nandrolone
UH / DSHS; Steraloids   
NARL
5β-BOLDG 5β-androst-1-en-3-one- 17β-O -glucuronide boldenone NARL
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Table 3. See the previous page for the title of the table. 
 
 
 
 
Abbreviation Compound Precursor Structure Source
5β-EPIMG
17β-methyl-5β-androst-
1-ene-17α-ol-              
3α-O -glucuronide
metandienone UH /DSHS
5β-MTG     
5β-LMTG*
17α-methyl-5β-
androstane-17β-ol-       
3α-O -glucuronide
metandienone   
methandriol   
methyltestosterone
UH / UH; Steraloids     
5β-NG 5β-estran-17-one-      3α-O -glucuronide nandrolone
UH / Steraloids         
NARL
7α-BOLAG
7α,17α-dimethyl-5β-
androstane-17β-ol-     
3α-O -glucuronide
bolasterone NARL
7β-CALUG
7β,17α-dimethyl-5β-
androstane-17β-ol-     
3α-O -glucuronide
calusterone NARL
AG 5α-androstane-17-one-
3α-O -glucuronide androsterone SIGMA / NARL
ETCG 5β-androstane-17-one-
3α-O -glucuronide etiocholanolone NARL
ETG
4-androsten-3-one-      
17α-O -glucuronide epitestosterone NARL
MTG
17α-methyl-4-
androsten-3-one-       
17β-O -glucuronide
methyltestosterone UH / DSHS
NG
estr-4-en-3-one-         
17β-O -glucuronide nandrolone UH / DSHS; Diosynth
TG
4-androsten-3-one-      
17β-O -glucuronide testosterone
UH / Makor Chemicals   
NARL
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protein was precipitated with dichloromethane, which also extracted the excess of starting 
material. The aqueous phase was removed and further purified in solid-phase extraction (SPE) 
with C18 cartridge (Figure 8). The AAS glucuronide fraction of SPE was evaporated to 
dryness in 60°C with nitrogen. The organic layer containing the excess of AAS aglycone was 
filtered (HV 0.45 µm, Millipore, USA), evaporated to dryness in a rotavapor system, and 
finally applied in the prospective AAS glucuronide synthesis. 
 
Mass spectrometric structure characterization of AAS glucuronides was performed with LC–
ESI-MS in positive ion mode and LC–ESI-MS/MS in positive and negative ion modes, 
according to the methods described in section 4.3.3. In NMR structure characterization, 
DQFCOSY, HMQC, and HMBC experiments were carried out with a Varian Unity 500 
instrument (I) with the AAS glucuronides dissolved in either acetone-d6 or methanol-d4. 
 
SAMPLE 
+ 
100 mM CH3COONH4 
in H2O; pH 4.5 (CH3COOH) 
100% water 
15 mM CH3COONH4 
in H2O; pH 4.5 (CH3COOH) 
100% methanol  
C18 Solid phase cartridge 
100 mg / 1 ml 
(International Sorbent Technology 
Great Britain) 
15 mM CH3COONH4 
in H2O; pH 4.5 (CH3COOH) 
100% water 
to dryness 
100% methanol 50-60% methanol in water
synthesis mixture kinetic studies 
 
Figure 8. Flowchart of solid-phase extraction procedures for AAS glucuronide bulk synthesis and 
kinetic studies. 
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4.3.2 UGT isoenzyme studies 
 
Enzyme kinetic assays were incubated in a total volume of 100 µl, the matrix consisting of 50 
mM phosphate buffer (pH 7.4, 5 mM MgCl2), 5 mM saccharic acid lactone, 5 mM UDPGA, 
and 0.5 mg/ml enzymatic protein (50 µg per assay). The same conditions were used in the 
studies with human liver (Gentest, Woburn, MA) and rat liver microsomal homogenates, both 
of which were pools of five individuals. The rat liver microsomal pool was the same as used 
for the bulk syntheses and it is described in section 4.3.1. Human UGTs of the studies were 
cloned and expressed in baculovirus-infected insect cells and prepared according to the 
method described by Kurkela et al., 2003. The activity of isoenzymes was confirmed with 
specific substrates; ethinylestradiol (UGT1A1), scopoletin (1A3, 2B15), 4-aminobiphenyl 
(1A4), α-naphtole (1A6), entacapone (1A7, 1A8, 1A9, 1A10), estriol (2B4), and morphine 
(2B7).     
 
Preliminary screening for glucuronidation was performed with a substrate concentration of 50 
µM. The glucuronidation reaction was initiated with UDPGA addition, carried out for two 
hours in a dry bath of 37°C, and finally terminated by precipitating the enzymatic protein with 
10 µl of 4 M perchloric acid. After centrifugation, the internal standard (5β-LMTG) was 
added to the supernatant, which was purified by SPE (Figure 8). The final eluate was 
evaporated to dryness and dissolved in LC–ESI-MS/MS buffer. For those isoenzymes that 
showed activity in the screening, the apparent Michaëlis-Menten constant, Km, was 
determined using substrate concentration levels of 1, 2.5, 5, 10, 25, 50, 100, 250, 500, and 
1000 µM. The peak areas of one specific ion of the analyte and one of the internal standard 
were plotted, v = A(ANAL)/A(ISTD), to obtain the variable (v) for calculations of Km. Calculations 
were done with Leonora Michaëlis-Menten software (Cornish-Bowden, version 1.0) with the 
least absolutes method. The structure-specific ions of the AAS glucuronides are presented in 
section 5.3.2.    
 
 
4.3.3 LC–ESI-MS/MS analysis of steroid glucuronides 
 
Initial characterization of the mass spectrometric (MS) and tandem mass spectrometric 
(MS/MS) behavior of the AAS glucuronides was done with direct infusion of the reference 
compounds to the ESI ion source (III). The samples were dissolved in an eluent consisting of 
7.5 mM ammonium acetate in water–methanol (50–50, V/V). In negative ion mode the eluent 
was neutral, whereas in positive ion mode the pH was adjusted to 4.2 with formic acid.  
 
The optimized LC method, which was applied both in enzyme kinetic studies and in the 
detection of AAS glucuronides in urine, utilized acetonitrile–water gradient and 15 mM 
ammonium acetate buffer. The pH of the eluent was adjusted to 4.2 with formic acid. An 
endcapped C18 column (Purospher RP-18e, 125 mm x 3.0 mm i.d., particle size 5 µm, Merck, 
Germany) was used for the chromatographic separation and a guard column of the same phase 
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material was also employed. The solvent flow rate of 0.5 ml/min was post-column split 
(Acurate, LC-Packings, The Netherlands) in the ratio of 1:10 before it was introduced to the 
turbo ionspray (TIS) ion source (IV). 
  
MS and MS/MS analyses were performed both in negative and in positive ion mode. The 
measurements were carried out mainly with the triple quadrupole MS, but the additional data 
of fragmentation were obtained from the experiments with the ion trap MS. Instrument details 
are given in Table 4. Although ESI ionization was used in the final application, the suitability 
of APCI was examined for eight AAS glucuronides (III). The fragmentation of the AAS 
glucuronides was studied in positive and negative ion mode MS/MS to identify structure-
specific AAS glucuronide fragments suitable for multiple reaction monitoring (MRM) in the 
LC–ESI-MS/MS method. Collision offset voltages were ramped within the range of 5–60 V, 
in the steps of 5 V. 
 
In the development of the LC–ESI-MS/MS method, a relatively new sample purification and 
concentration method, liquid-phase microextraction (LPME), was developed for urinary AAS 
glucuronides. This was finally compared with the modified LLE (Thevis et al., 2001a) and 
standard SPE procedures (Borts and Bowers, 2000). LPME optimization and the details of the 
LLE and SPE procedures are described in paper IV. 
 
 
 
Table 4. Description of the liquid chromatography–mass spectrometry (LC–MS) instrumentation 
applied in the study. Atmospheric pressure chemical ionization (APCI); atmospheric pressure 
photoionization (APPI); electrospray ionization (ESI); turbo ionspray (TIS). 
 
LIQUID CHROMATOGRAPHS
Abbreviation Type Producer Country Autosampler Pump
LC1 Series 1100 Agilent Germany G1367A G1312A binary
LC2 Series 1100 Agilent Germany G1313A G1312A binary
LC3 LC 200 micro Perkin Elmer USA Series 200 Series 200 micro
MASS SPECTROMETERS
Abbreviation Type Producer Country Analyzer type Ion sources
MS1 API 300 PE Sciex Canada triple quadrupole ESI, APCI
MS2 API 3000 Applied Biosystems Canada triple quadrupole ESI, TIS, APPI
MS3 Esquire Bruker Germany LC ion trap ESI
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5. RESULTS AND DISCUSSION 
 
The main results obtained in this work are shortly described in this section. More details can 
be found in the original publications I–IV.  
 
 
5.1 ENZYME-ASSISTED SYNTHESIS OF AAS GLUCURONIDES 
 
Optimization of AAS glucuronide synthesis was carried out in small-scale studies, with a total 
incubation volume of 100 µl. Glucuronidation activity was followed as a function of steroid 
substrate concentration, UDPGA concentration, protein amount, and incubation time (Figure 
9). Rat liver microsomes were found to be capable of conjugating all the tested steroid 
aglycones, and only slight differences were detected in the optimal conditions for the various 
substrates (Table 5).  Substrate inhibition was not observed for any of the steroids within the 
concentration range of 1–1000 µM, but a plateau of glucuronidation was reached at 500–1000 
µM, except for 5α-NG, for which it was 250 µM. The first point of the plateau was selected 
as the substrate concentration for the further synthesis. The most probable reason for the 
limited formation of AAS glucuronide was the sparing solubility of the non-polar steroid 
substrate in phosphate buffer. The amount of organic modifier, which was methanol, was 
limited to approximately 10% because of potential precipitation of the enzymatic protein.  
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Figure 9. Optimization of conditions of AAS glucuronide synthesis for 5α-NG. Formation of the 
conjugate as function of A) substrate concentration, B) UDPGA concentration, C) microsomal protein 
concentration, and D) incubation time. Constant conditions: 50 µM substrate,5 mM UDPGA, 0.5 
mg/ml protein, and 2 hrs incubation time.    
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Optimal concentration of the co-substrate, UDPGA, was 2.5–5 mM, except for 
methyltestosterone, which required 7.5 mM UDPGA for maximal production of MTG. The 
formation of the glucuronide conjugates was linearly proportional to the amount of protein 
and became optimal when the amount of protein was 0.5–1 mg/ml. The effect of incubation 
time was examined up to 24 hours. Glucuronidation was linear within the first six hours, but 
because there was no evidence of breakdown of the AAS glucuronide with longer reaction 
times, the incubations were carried out overnight (12–15 hours). 
 
 
Table 5. Parameters selected for the optimized synthesis of AAS glucuronides. Positions of deuterium 
label indicated with an asterisk. See Table 3 for nomenclature.  
 
Abbreviation Structure Substrate (µM) UDPGA (mM) Protein (mg/ml)
5α-1-MEG 500 5 1
5α-AG      
d5-5α-AG 500 2.5 1
5α-MEG 500 2.5 0.75
5α-MTG 1000 2.5 0.5
5α-NG      
d4-5α-NG 250 5 1
5β-EPIMG 500 5 1
5β-MTG     
5β-LMTG 1000 2.5 0.5
5β-NG 500 5 0.75
MTG 1000 7.5 0.5
NG         
d3-NG 500 5 1
d3-TG 500 5 1
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The excess starting material (steroid substrate) was removed in liquid–liquid extraction (LLE) 
with dichloromethane, which also simultaneously precipitated the enzymatic protein and 
stopped the conjugation reaction. Although LLE enabled the collection and recycling of the 
precious starting material, some residues were detected in the aqueous glucuronide fraction. 
An additional solid-phase extraction (SPE) step was therefore attached to the procedure. 
Retention of the steroid substrate and the glucuronide conjugate was examined as a function 
of methanol percentage (0-100%) in the SPE eluent in intervals of 10% (Figure 10). The 
difference between the polarities of the two compounds was sufficient for the complete 
isolation of the AAS glucuronide when methanol–water (60–40, V/V) was applied in the final 
elution.   
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Figure 10. Elution of AAS glucuronide and non-reacted steroid aglycone from the reaction mixture of 
5α-1-MEG (A) and NG (B) as function of methanol concentration in the eluent of solid-phase 
extraction.  
 
 
Fourteen AAS glucuronides, including four deuterium-labeled analogues, were synthesized in 
milligram amounts (1.3-6.5 mg) with yields of 13-78% (Table 6). A significant difference was 
observed between the yields of NG, d3-NG, and d3-TG, which are 4-ene-3-one structured 
substrates, and the yields of other substrates, the former showing superior yields of 77-78% 
and the latter yields of 13-28%.  
 
Table 6. List of synthesized steroid glucuronides and their yields. 
 
Compound Yield (mg) Yield (%) Compound Yield (mg) Yield (%)
5α-1-MEG 1.7 24 5β-EPIMG 1.4 25
5α-AG 1.9 16 5β-MTG 2.6 26
d5-5α-AG 2.1 26 5β-NG 1.1 13
5α-MEG 2.5 28 MTG 1.2 14
5α-MTG 2.1 22 NG 3.5 77
5α-NG 1.3 16 d3-NG 4.4 78
d4-5α-NG 1.7 18 d3-TG 6.5 77
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Although methyltestosterone also has 4-ene-3-one structure, the yield of MTG was 
exceptionally low, 14%. The only possible conjugation site of methyltestosterone is the 
sterically hindered 17β-hydroxyl group, which has earlier been proposed to inhibit the 
catalysis of the bulky UGT enzymes. According to Schänzer, 1996, there is evidence of 17β-
glucuronidation for metandienone, fluoxymesterone, and 4-chloro-1,2-dehydro-17α-
methyltestosterone, though detailed results have not been published. On the basis of the 
formation of MTG, but in low yield, it is proposed here that the 17α-methyl-17β-hydroxyl 
structure, while not favorable for glucuronidation, nevertheless, allows some conjugation in 
the absence of a more favorable hydroxyl group. The formation of 5β-EPIMG supports the 
suggestion, as conjugation occurs with the 3α-hydroxyl group rather than with the epimeric 
17β-methyl-17α-hydroxyl structure. The syntheses with the rat liver microsomal preparation 
were not significantly affected by the orientation of the 5α/β-proton, because the yields of 
isomeric pairs 5α-NG and 5β-NG, as well as of 5α-MTG and 5β-MTG were closely identical.  
 
Characterization of the AAS glucuronides was carried out by mass spectrometric (MS; see 
section 5.3.2) and nuclear magnetic resonance (NMR) analyses, which confirmed the 
structures of the synthesized conjugates (I). The substrates with two hydroxyl groups, and 
thus two potential sites for conjugation, were of special interest in the NMR studies. 
Substrates having both a tertiary 17-hydroxyl group (either 17α- or 17β-oriented) and a 3α-
hydroxyl group, that is, aglycones 5β-EPIM, 5α-MT, and 5β-MT, formed 3-O-glucuronides, 
whereas 5α-A, with a secondary 17β-hydroxyl group and a 3α-hydroxyl group, formed 17-O-
glucuronide. 
 
Systematic stability testing of the AAS glucuronides was not carried out, but methylation of 
the glucuronic acid group was observed after a two-week period in acidic methanolic solution. 
A follow-up of our synthesis products showed that the storage either as dry substance or in 
neutral aprotic environment, such as in acetonitrile, is sufficient to prevent the degradation of 
the AAS glucuronides at least during six months. 
 
The absolute amounts of AAS glucuronides produced in the enzyme-assisted synthesis were 
relatively small and the procedure was carried out completely manually. For LC–MS/MS 
method development purposes the amount of reference material was clearly sufficient, 
enabling thousands of injections. The procedure would hardly be suitable, however, for 
scaling up or commercializing of the enzymatic synthesis. Although a larger volume of 
reaction mixture would provide more of the synthesis product, the higher consumption of 
UDPGA would increase the cost of the synthesis dramatically. One approach to enhancing the 
production would be to screen for microsomal UGT enzymes in other rat races or animal 
species. The use of liver preparations for bulk synthesis would require sacrifice of many 
animals, and run into severe ethical problems. Probably, however, the most critical point in 
the method development is to increase the solubility of the steroid aglycone in the reaction 
mixture without damaging the UGT enzymes. It would be sensible to explore the use of 
additives such as phospholipids, bovine serum albumin, and cyclodextrins rather than 
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applying a high concentration of organic solvent, although the addition of new components to 
the reaction would demand a careful re-evaluation of the purification procedure. A higher 
level of automation could be achieved by applying preparative or semi-preparative HPLC 
fractioning to the purification of the AAS glucuronides.  
 
 
5.2 SUBSTRATE SPECIFICITY OF RECOMBINANT UGT ISOENZYMES 
 
The activity of 11 human recombinant UGTs toward 11 AAS substrates was examined to 
determine the possible of regio- or stereoselectivity of the UGTs (Table 7). The structures of 
the AAS substrates in the study were closely related, and the only potential sites of 
conjugation were the 3α-, 17α-, and/or 17β-hydroxyl group(s) in various combinations. LC–
ESI-MS/MS method was used in the detection of the AAS glucuronides that formed. 
Comparison of the results of these studies with the results obtained with human and rat liver 
microsomal preparations was made to determine whether the UGT isoenzymes could be used 
as an in vitro model of AAS glucuronidation and in regio- and stereospecific production of 
AAS glucuronides (II). 
 
The activity of isoenzymes was confirmed with known substrates, as described in section 
4.3.2. Methanol, ethanol, and dimethyl sulfoxide (DMSO) were all tested at the levels of 5% 
and 10% in reaction mixture to ensure the maximal solubility of the non-polar steroid 
substrate with minimal interference with the enzyme function (Figure 11). From these solvent 
environments especially ethanol was found to have a crucial effect on the protein, and 10% 
DMSO was selected for the following screening of the glucuronidation. Similar sensitivity to 
organic solvent was not detected for liver microsomal preparations.   
 
Among the UGTs, the only isoenzymes without detectable conjugation activity for any of the 
tested steroid substrates were UGT1A6 and UGT1A7. The behavior of UGT1A10 was 
exceptional, and it was as an enzyme of its own class, possessing both high substrate 
selectivity and high activity toward the test compounds. The other the enzymes could be 
divided into two main groups: group A enzymes (UGT1A1, 1A8, 1A9, and 2B15) with weak 
but selective glucuronidation activity, and group B enzymes (UGT1A3, 1A4, 2B4, and 2B7) 
with high activity toward most substrates. With respect to regioselectivity, most UGTs did not 
show a clear preference in glucuronidation for the 3α- or the 17β-hydroxyl group, as all of the 
tested enzymes that were active in the formation of 3α-O-glucuronides also catalyzed the 
production of 17β-O-glucuronides. Exceptional isoenzymes were UGT1A8, 1A9, and 2B15, 
which appeared to preferentially catalyze 17β-O-glucuronidation. This is in good accordance 
with the results obtained for UGT2B15 (Chen et al., 1993; Green et al., 1994). Among the 
AAS glucuronides, 5α-AG was of particular interest because regioselective conjugation has 
been reported to occur in either the 17β-hydroxyl group (Rittmaster et al., 1988; Beaulieu et 
al., 1996) or the 3α-hydroxyl group (Jin et al., 1997).  
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Table 7. Substrate specificity of UGT isoenzymes toward steroid aglycones. + = Detected formation of glucuronide conjugate (increase of symbol amount 
highlighting the difference of two decades of peak area); - = No evidence of steroid glucuronide formation; * = Evidence of substrate inhibition; n.d. = not 
determined. 
  
UGT 5α-N 5β-N 5α-ME MT 5α-MT 5β-MT 5β-EPIM T N 5α-1-ME 5α-A
1A1 + + - - - - - + + - ++
K m 375 µM 55 µM 16 µM 38 µM
1A3 + ++ ++ - + + + ++ ++ + ++
K m n.d. 136 µM 37 µM 12 µM 12 µM n.d. 131 µM 44 µM n.d. 33 µM
1A4 + ++ ++ - ++ ++ - + ++ ++ ++
K m 4 µM 55 µM 36 µM 7 µM 19 µM 44 µM 32 µM 26 µM 28 µM
1A6 - - - - - - - - - - -
K m
1A7 - - - - - - - - - - -
K m
1A8 - - - - - - - + ++ + ++
K m 72 µM 72 µM 70 µM 9 µM
1A9 - - - - - - - + + + ++
K m 61 µM 81 µM n.d. 21 µM
1A10 - + - - - - + ++ ++ ++ ++
K m 45 µM n.d. 60 µM 47 µM 46 µM 14 µM
2B4 + ++ ++ - + + ++ + + + ++
K m n.d. 17 µM 21 µM n.d. n.d. n.d. 6 µM 31 µM n.d. 5 µM
2B7 ++ ++ ++ - + ++ ++ + + + ++
K m 21 µM n.d. n.d. 19 µM * * * * * *
2B15 - - - - - - - + + + ++
K m n.d. n.d. n.d. *
Human ++ +++ +++ + ++ ++ +++ ++ ++ ++ +++
Rat liver ++ +++ +++ +++ ++ +++ +++ +++ +++ ++ +++
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In this study, 5α-AG was the only AAS glucuronide to form abundantly with every active 
isoenzyme, but unfortunately, in the small incubation volumes of the study, the amount of the 
resulting conjugate was too small for NMR determination of the conjugation site. The 
behavior of methyltestosterone was also unusual, as the formation of MTG was not detected 
with any of the UGT isoenzymes. Until now, the liver has been considered as the main site of 
steroid glucuronidation (Hum et al., 1999) with members of the subfamily UGT2B mainly in 
charge of the conjugation. The formation of AAS glucuronides by members of the subfamily 
UGT1A, especially by gastrointestinal isoenzymes UGT1A8 and UGT1A10, was thus a 
highly interesting finding. 
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Figure 11. Effect of organic solvent on the formation of 5α-AG with UGT2B15. Amount of the formed 
glucuronide expressed as area ratio to internal standard 5β-LMTG. Abbreviations: MeOH=methanol, 
EtOH=ethanol, and DMSO=dimethyl sulfoxide.  
 
 
Stereoselective glucuronidation by UGT2B7 of an endogenous 5α/β-diasteromeric pair, 
androsterone and etiocholanolone, has been reported by Jin et al. (1997). The orientation of 
the proton has a dramatic effect on the steroid ring structure, as the A/B-cis junction of 5β-
steroids changes the spatial ring geometry to a severely bent form and the 3α-bond to 
equatorial orientation: 5α-steroids, in turn, exhibit the planar A/B ring system with axial 3α-
bond  (Kirk and Marples, 1995). In the present study, stereoselectivity was detected in the 
formation of the conjugated nandrolone metabolites 5α-NG and 5β-NG (Table 7), as the 
formation of 5β-NG was favored over 5α-NG with most of the UGT isoenzymes (UGT1A1, 
1A3, 1A4, 1A10, and 2B4). In contrast to 5α-NG and 5β-NG, no stereoselectivity was 
detected in the formation of 5α-MTG and 5β-MTG. Also, differing from earlier results, 
UGT2B7 did not show clear selectivity toward the orientation of C-5 hydrogen. 
 
The observed differences in substrate specificity between the structurally highly homologous 
isoforms (Figure 4) were actually due more to the activities of the enzymes than the substrate 
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specificity. Thus, isoenzymes UGT1A8, 1A9, and 1A10 in most cases were active toward the 
same substrates, namely those that were planar and possessed the 17β-hydroxyl group for 
conjugation (T, N, 5α-1-ME, and 5α-A). Glucuronidation of 5β-N and 5β-EPIM only with 
1A10 were exceptions to this rule. Considering the isoenzyme homology, UGT1A7 was 
exceptional in that it was not active toward any of the steroid substrates (Table 7). Substrate 
selectivity of two other closely similar isoenzymes, UGT1A3 and 1A4, was virtually 
identical: they were active toward the same substrates and toward most substrates of the 
study; the conjugation of 5β-EPIM solely with UGT1A3 was the only observed deviation. 
Nevertheless, differences were observed between the activities of UGT1A3 and 1A4 in the 
formation of 5α-MTG, 5β-MTG, TG, and 5α-1-MEG.  
 
To characterize the affinity of the different UGTs for the steroid substrates, reaction kinetics 
was examined by determining the apparent Km, i.e. the Michaëlis-Menten constant. The 
UGT2B subfamily members are often referred to as steroid metabolizing enzymes. In this 
study, the observed Km values fully support that characterization, as in most cases the Km 
values for a given substrate were lower for UGT2B4 and 2B7 than for members of the 
UGT1A subfamily (Table 7). An exceptionally high Km value was obtained in the formation 
of 5β-NG with UGT1A1 (375 µM), indicating low affinity of the isoenzyme toward the 
substrate. Similarly to UGT1A1, Km was also high for 5β-N formed with UGT1A3. Despite 
the close similarity of the amino acid sequences, significant differences were detected 
between the affinities of UGT1A3 and 1A4 in the formation of 5β-NG (136 vs. 55 µM) and 
TG (131 vs. 44 µM). For the other substrates that showed glucuronidation with UGT1A3 and 
1A4, the apparent Km values were closely similar (Table 7). Apparent Km values obtained with 
homologous enzymes UGT1A8, 1A9, and 1A10 for substrates T, N, 5α-1-ME, and 5α-A 
were also closely similar to each other. Although UGT2B7 is reported to have only one 
binding site for xenobiotics and endobiotics, its catalytic capacity was high in inhibition 
studies for in vivo drug–drug interactions with opioid substrates (Rios and Tephly, 2002). In 
view of this finding, it was unexpected to observe substrate inhibition, which interfered 
heavily the determination of Km with UGT2B7 for most of the present steroid substrates 
(Table 7). These results, however, were obtained in the methanolic environment, and 
therefore, should be confirmed with DMSO to exclude the solvent effects on isoenzymes.   
 
The most significant difference in steroid glucuronidation with human recombinant UGTs, 
human liver preparation, and rat liver preparation was observed for methyltestosterone, which 
was not conjugated with any isoenzyme, only scarcely with human liver microsomal UGTs, 
but to high extent with induced rat liver microsomal UGTs. The possible correlation between 
AAS glucuronidation with isoenzymes and with human liver microsomes was studied by 
determining the relative activities of the enzyme preparations toward different aglycones. To 
minimize the effect of the various expression levels of the enzymes, the activities obtained for 
a particular preparation were normalized to the formation of 5α-AG. 
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Table 8. Glucuronidation of the steroid substrates relative to the glucuronidation of 5α-androstane-
3α,17β-diol (5α-A). Comparison of the human liver preparate with selected UGT isoenzymes. 
 
Structure Substrate
Human liver 
microsomes UGT1A3 UGT1A4 UGT2B4 UGT2B7 UGT1A10
5β-N 1.423 0.565 0.040 1.232 6.809 0.022
5α-A 1.000 1.000 1.000 1.000 1.000 1.000
5β-EPIM 0.748 0.030 - 5.907 2.018 0.024
5α-ME 0.539 2.998 0.439 2.702 0.699 -
T 0.073 0.236 0.013 0.003 0.029 0.085
5β-MT 0.068 0.079 0.138 0.097 0.177 -
N 0.062 0.196 0.029 0.007 0.004 0.796
5α-N 0.047 0.097 0.014 0.033 0.248 -
5α-1-ME 0.039 0.031 0.170 0.020 0.034 0.896
5α-MT 0.035 0.079 0.060 0.095 0.068 -
MT 0.0002 - - - - -
Formation of steroid glucuronides relative to 5α-AG
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According to the results of experiments measuring the relative aglycone preference, 
glucuronidation patterns of the hepatic isoenzymes UGT1A3, 1A4, 2B4 and 2B7 generally 
resembled the glucuronidation pattern of human liver microsomes (Table 8). Comparison of 
the different glucuronidation assays suggested that, with the set amount of membrane protein 
used (mg protein/incubation), the activity of the recombinant isoenzymes was significantly 
lower than that of the liver preparations. One possible reason for this is the difference between 
the expression levels of individual UGTs in liver preparations, but also the organic solvent in 
the reaction mixture may interfere differently with the activity of the different recombinant 
enzymes. 
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5.3 LC–ESI-MS/MS ANALYSIS OF AAS GLUCURONIDES 
 
Radioactivity detection based on the use of 14C-labeled UDPGA was investigated at an early 
stage of the development of an enzyme kinetic assay for AAS glucuronides. Because of the 
low yield of the glucuronidation reaction and small amount of the 14C-labeled AAS 
glucuronide, however, the poor sensitivity and high price of the labeled co-substrate became 
restrictive in application of the method. Most AAS glucuronides in the study did not possess 
either chromophores or fluorophores, which also excluded the use of UV or fluorescence 
detectors. Instead, mass spectrometric detection in combination with API techniques was 
investigated as a suitable approach in the method development. Because of the ionization 
mechanism, only volatile buffers and additives are suitable with the LC–ESI-MS/MS system. 
For the analyst this often means that modifications must be made to traditional high-
performance liquid chromatographic (HPLC) methods, which typically rely on phosphate or 
citrate buffer.  
 
 
5.3.1 Liquid chromatography 
 
Although MS was used as the detector, the method development was focused on 
chromatographic separation of the glucuronides, because of the particular analytes with the 
same precursor ion and similar product ion spectra. Moreover, separation was considered 
advantageous to maintain the dynamic range and to minimize the risk of ion suppression in 
electrospray ionization (ESI). Acetonitrile rather than methanol was chosen as the organic 
modifier because of its slightly higher resolving power. The difference between acetonitrile 
and methanol was most evident in the separation of the nandrolone metabolites 5α-NG and 
5β-NG, which completely co-eluted when methanol gradients were applied. Switching to 
acetonitrile did not solve the problem completely, but it provided partial separation with the 
resolution Rs=0.5. Moderately high ammonium acetate concentration, 15 mM, was required to 
achieve acceptable peak widths and shapes, and the eluent pH was adjusted to 4.2 according 
to an earlier method introduced for the LC–ESI-MS/MS analysis of TG and ETG (Bowers 
and Sanaullah, 1996). 
 
An endcapped C18 column with linear acetonitrile gradient was applied in the final LC method 
(II, IV). Within the total analysis time of 15 minutes, AAS glucuronides eluted in 3–8.5 min, 
and most of the isobaric analytes with similar MS/MS behavior were clearly separated (IV). 
Orientation of the relatively bulky and highly polar glucuronide moiety had a significant 
effect on separation of the isomers: TG (17β-O-glucuronidation) and ETG (17α-O-
glucuronidation) was the most clearly separated pair, with resolution Rs=13.0. The pair of 
regioisomers 5α-MESM1G/5α-DROSTG was also clearly separated (Rs=3.3). Orientation of 
a methyl group (7α/7β) was sufficient to produce chromatographic separation in C18 column, 
where 7α-BOLAG and 7β-CALUG were clearly distinguishable (Rs=1.9). In some cases even 
5α/β orientation of a proton led to separation, for example, AG from ETCG (Rs=1.2); and, as 
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described above, 5α-NG was to some extent separated from 5β-NG (Rs=0.5). The group 
consisting of three isomers, 5α-MTG, 5β-MTG, and 5α-MESM2G, was slightly more 
problematic, as the diastereomers 5α-MTG and 5β-MTG completely co-eluted. However, 
their regioisomer 5α-MESM2G was separated with Rs=0.76 from the first two compounds.  
 
A column with narrower internal diameter (Luna C18, 150 mm x 1.0 mm i.d., particle size 5 
µm, Phenomenex, CA, USA) was tested in the development stage with the solvent flow rate 
decreased to 100 µl/min. Despite the slightly improved resolution, better separation was not 
achieved for 5α-MTG/5β-MTG/5α-MESM2G. Additionally, the analysis time expanded to 
30 min, mainly due to the equilibration step after the gradient, and irreproducibility was still 
observed in the retention times. This result suggests the use of the micro-LC pumps that are 
specially designed for the handling of gradients with low solvent flow rates.  
 
 
5.3.2 Mass spectrometry (MS) and tandem mass spectrometry (MS/MS) 
 
Electrospray ionization (ESI) was suitable for the ionization of every glucuronide-conjugated 
analyte of the study, both in positive and negative ion mode (III, IV). In positive ion ESI the 
ratio of the protonated molecule [M+H]+ to the corresponding ammonium adduct [M+NH4]+ 
was found to depend strongly on the structure, i.e. on the proton affinity of the compound, the 
high proton affinity (PA) of conjugated double bond systems favoring the formation of 
protonated form. This was nicely observed with ETG, MTG, NG and TG with 4-ene-3-one, as 
well as in the spectra of 5α-1-MEG and 5β-BOLDG with 1-ene-3-one structure (Table 3). For 
the analytes with saturated A-ring, and thus with lower PA (Harrison, 1982), the [M+H]+ was 
often totally absent from the spectra, or its relative abundance was below 10%. In comparison 
with the other AAS glucuronides, the ionization efficiency of 3-OHSTG was exceptionally 
high. It is present in ionized form at the eluent pH of 4.2 and, furthermore, the basic pyrazol 
ring most probably allows the proton transfer reaction in the gas phase. As a result, strong and 
stabile [M+H]+ was the base peak of positive ion ESI of 3-OHSTG, without [M+NH4]+.  
 
In negative ion ESI an intensive deprotonated molecule [M-H]- was observed as the base peak 
of all AAS glucuronides (Table 9). Because the steroid aglycones were not ionized in 
negative ion ESI, it is likely that the deprotonation occurs in the carboxylic acid moiety of the 
glucuronic acid part of the conjugate. 
 
In positive ion MS/MS the precursor ion was either [M+H]+ or [M+NH4]+, according to 
results in MS studies. The main fragments were produced by losses of one or two water 
molecules from the precursor ion [M+H-nH2O]+ and by subsequent neutral cleavage of the 
glucuronide moiety [M+H-Glu-nH2O]+. The positive charge stayed predominantly on the 
aglycone side in the dissociation process, and only weak fragment ions were derived from the 
glucuronide moiety; e.g. [Glu+H]+=177, [Glu+H-H2O]+=159,  [Glu+H-2H2O]+=141. The 
origin of these fragments was investigated in MSn measurements with the ion trap instrument. 
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Since neither the steroid glucuronide nor the cleaved aglycone produced the ions m/z 177, 
159, or 141 in consecutive isolation and fragmentation steps, these ions were most probably 
fragments of the glucuronide moiety (Figure 12).  
 
 
Table 9. Positive and negative ion ESI MS of AAS glucuronides; m/z (rel. abundance), n.d. = 
not detected.  See Table 3 for structures and nomenclature. 
NEG ESI
Compound [M+H]
+ [M+NH4]
+ [M+Na]+ [M-H]-
3-OHSTG 521 (100) n.d. 543 (76) 519 (100)
5α-1-MEG 479 (89) 496 (100) 501 (11) 477 (100)
5α-AG n.d. 486 (100) 491 (6) 467 (100)
5α-DHTG 467 (9) 484 (39) 489 (100) 465 (100)
5α-DROSTG 481 (3) 498 (41) 503 (100) 479 (100)
5α-MEG 479 (2) 496 (57) 501 (100) 477 (100)
5α-MESM1G 481 (2) 498 (46) 503 (100) 479 (100)
5α-MESM2G 483 (3) 500 (48) 505 (100) 481 (100)
5α-MTG n.d. 500 (100) 505 (36) 481 (100)
5α-NG n.d. 470 (100) n.d. 451 (100)
5β-BOLDG 465 (76) 482 (24) 487 (100) 463 (100)
5β-EPIMG n.d. 498 (100) n.d. 479 (100)
5β-MTG n.d. 500 (100) 505 (38) 481 (100)
5β-NG n.d. 470 (100) 475 (43) 451 (100)
7α-BOLAG 497 (2) 514 (49) 519 (100) 495 (100)
7β-CALUG 497 (3) 514 (45) 519 (100) 495 (100)
AG 467 (3) 484 (100) 489 (15) 465 (100)
ETCG n.d. 484 (100) 489 (83) 465 (100)
ETG 465 (100) 482 (77) 487 (42) 463 (100)
MTG 479 (94) 496 (100) 501 (15) 477 (100)
NG 451 (100) n.d. 473 (50) 449 (100)
TG 465 (100) 482 (22) 487 (48) 463 (100)
Deuterated 
compound [M+H]+ [M+NH4]
+ [M+Na]+ [M-H]-
5β-LMTG n.d. 503 (100) 508 (76) 484 (100)
d4-AG n.d. 488 (100) 493 (61) 469 (100)
d3-5α-DHTG 470 (8) 487 (36) 492 (100) 468 (100)
d3-ETG 468 (74) 485 (100) 490 (98) 466 (100)
d3-TG 468 (100) 485 (41) 490 (66) 466 (100)
POS ESI
 
 
Collision offset voltages were optimized to produce structure-specific product ions of AAS 
glucuronides for the multiple reaction monitoring (MRM) in LC–ESI-MS/MS. These were 
ions that originated from the steroid aglycone, i.e. [M+H-Glu-nH2O]+. Selected collision 
offset voltages were 20–35 V, with slightly higher voltages for 17-O-conjugated than for 3-O-
conjugated AAS glucuronides (Table 10). The fragmentation behavior of 3-OHSTG was 
unique: the only product ion at the optimal collision offset voltage (25 V) was the steroid 
aglycone [M+H-Glu]+=345. Most probably this was because of the presence of the pyrazole 
ring, which is capable of resonance stabilization of the positive charge. Further increment of 
collision energy led only to the formation of fragments in low abundance in the low m/z 
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region. Thus, monitoring of a single target ion was possible with 3-OHSTG. Among the 
studied AAS glucuronides there were several groups of isobaric analytes with similar product 
ion spectra: TG/ETG, 5α-NG/5β-NG, 5α-MTG/5β-MTG/5α-MESM2G, 5α-MESM1G/5α-
DROSTG, 7α-BOLAG/7β-CALUG, and AG/ETCG (Table 3). In positive ion MS/MS it was 
possible to distinguish between TG and ETG, where the isomerism occurs specifically at the 
conjugation site 17β/α-OH. The molecular strain is clearly greater in ETG than in TG because 
the precursor ion [M+H]+ of ETG was significantly less stable than that of TG. With the 
nandrolone metabolites 5α-NG and 5β-NG, differences were seen in the stability of 
[M+NH4]+, which was higher for 5β-NG than for 5α-NG. Furthermore, at the optimal 
collision offset voltage the ratio of the relative abundances of product ions [M+H-
Glu]+/[M+H-Glu-H2O]+ was significantly higher for 5β-NG than for 5α-NG, which allowed 
the two diastereomers to be distinguished. Mesterolone metabolite 5α-MESM2G could be 
distinguished from the methyltestosterone metabolites 5α-MTG and 5β-MTG, because the 
relative abundance ratio of ions [M+H-Glu-H2O]+/[M+H-Glu-2H2O]+ was higher for 5α-
MESM2G than for 5α-MTG and 5β-MTG. Compounds 5α-MTG/5β-MTG, 5α-
MESM1G/5α-DROSTG, 7α-BOLAG/7β-CALUG, and AG/ETCH yielded identical spectra 
at every collision offset voltage and thus were indistinguishable without chromatographic 
separation. 
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Figure 12. An example of MSn studies with androsterone glucuronide (AG). A) Positive ion MS 
spectrum, B) MS/MS spectrum of [M+NH4]+=484, and C) MS/MS/MS spectrum of [M+H-Glu-
2H2O]+=255. Suggested glucuronic acid fragments [Glu+H]+=177, [Glu+H-H2O]+=159, [Glu+H-
2H2O]+=141 were not detected. 
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Table 10. Positive ion mode ESI-MS/MS; m/z (rel. abundance), n.d. = not detected. See Table 3 for structures and nomenclature. Collision offset voltage noted for 
each analyte. The table continues in the next page. 
 
 
 
Ions 3-OHSTG 25 V
5α-1-MEG 
30 V
5α-AG   
20 V
5α-DHTG 
25 V
5α-DROSTG 
20 V
5α-MEG 
20 V
5α-MESM1G 
20 V
5α-MESM2G 
20 V
5α-MTG 
20 V
5α-NG   
20 V
5β-BOLDG 
20 V
5β-EPIMG 
20 V
5β-MTG   
20 V
Precursor
[M+NH4]
+ 496 (1) 486 (4) 484 (1) 498 (7) 496 (7) 498 (3) 500 (4) 500 (13) 470 (11) 498 (5) 500 (9)
[M+H]+ 521 (100) 465 (11)
Product ions
[M+NH4-NH3]
+  479 (100) n.d. 467 (2) 481 (1) 479 (1) 481 (1) 483 (1) n.d. 453 (6) 481 (4) n.d.
[M+NH4-H2O]
+ n.d. n.d. n.d. n.d. n.d. n.d. n.d. 482 (4) n.d. 482 (4)
[M+H-H2O]
+ n.d. n.d. 451 (7) 449 (1) 463 (14) 461 (6) 463 (21) 465 (7) 465 (15) 435 (28) 447 (5) n.d. 465 (13)
[M+H-2H2O]
+ n.d. n.d. 433 (1) n.d. 445 (8) 443 (2) 445 (7) 447 (2) 447 (5) 417 (74) 431 (3) n.d. 447 (7)
[M+H-Glu]+ 345 (18) 303 (18) n.d. 291 (20) 305 (9) 303 (8) 305 (5) n.d. n.d. 277 (60) 289 (100) 305 (3) n.d.
[M+H-Glu-H2O]
+ n.d. 285 (11) 275 (34) 273 (100) 287 (100) 285 (100) 287 (100) 289 (100) 289 (44) 259 (100) 271 (21) 287 (4) 289 (58)
[M+H-Glu-2H2O]
+ n.d. 267 (4) 257 (100) 255 (48) 269 (28) 267 (10) 269 (39) 271 (48) 271 (100) 241 (14) 253 (5) 269 (100) 271 (100)
[Glu+H]+ n.d. 177 (1) 177 (13) 177 (8) 177 (12) n.d. 177 (15) 177 (20) 177 (19) 177 (22) n.d. 177 (2) 177 (6)
[Glu+H-H2O]
+ n.d. 159 (4) 159 (7) 159 (24) 159 (4) 159 (1) 159 (5) 159 (5) 159 (7) 159 (16) 159 (4) 159 (1) 159 (3)
[Glu+H-2H2O]
+ n.d. 141 (5) 141 (6) 141 (71) 141 (4) 141 (1) 141 (7) 141 (5) 141 (5) 141 (16) 141 (3) n.d. 141 (4)
Steroid glucuronide
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Table10. See the previous page for the title of the table. 
 
 
 
Ions 5β-NG   20 V
7α-BOLAG 
20 V
7β-CALUG 
20 V
AG     
25 V
ETCG   
25 V
ETG     
25 V
MTG    
30 V
NG      
30 V
TG      
25 V
5β-LMTG 
20 V
d4-AG   
25 V
d3-5α-DHTG 
25 V
d3-ETG  
25 V
d3-TG    
25 V
Precursor
[M+NH4]
+ 470 (100) 514 (4) 514 (2) 484 (1) 484 (1) 496 (2) 503 (3) 488 (1) 487 (1)
[M+H]+ 465 (0) 451 (100) 465 (100) 468 (1) 468 (100)
Product ions
[M+NH4-NH3]
+ 453 (23) n.d. n.d. 467 (1) 467 (1) 479 (100) n.d. 471 (1) 470 (3)
[M+NH4-H2O]
+ n.d. 496 (1) 496 (1) n.d. n.d. n.d. 485 (1) n.d. n.d.
[M+H-H2O]
+ 435 (21) 479 (4) 479 (2) 449 (5) 449 (2) n.d. 461 (2) n.d. n.d. 468 (4) 453 (3) 452 (1) n.d. n.d.
[M+H-2H2O]
+ 417 (92) 461 (1) 461 (4) 431 (14) 431 (21) n.d. n.d. n.d. n.d. 450 (3) 435 (22) n.d. n.d. n.d.
[M+H-Glu]+ 277 (67) n.d. n.d. 291 (20) 291 (48) 289 (99) 303 (32) 275 (71) 289 (55) n.d. 295 (23) 294 (21) 292 (56) 292 (45)
[M+H-Glu-H2O]
+ 259 (42) 303 (33) 303 (66) 273 (100) 273 (100) 271 (100) 285 (71) 257 (24) 271 (14) 292 (48) 277 (100) 276 (100) 274 (100) 274 (13)
[M+H-Glu-2H2O]
+ 241 (13) 285 (100) 285 (100) 255 (63) 255 (61) 253 (29) 267 (34) 239 (14) 253 (10) 274 (100) 259 (47) 258 (36) 256 (18) 256 (8)
[Glu+H]+ 177 (4) 177 (1) 177 (4) 177 (20) 177 (4) 177 (5) 177 (9) n.d. 177 (1) 177 (3) 177 (16) 177 (14) n.d. 177 (5)
[Glu+H-H2O]
+ 159 (4) 159 (1) 159 (2) 159 (37) 159 (12) 159 (16) 159 (15) 159 (12) 159 (9) 159 (5) 159 (26) 159 (21) 159 (12) 159 (8)
[Glu+H-2H2O]
+ 141 (5) 141 (1) 141 (3) 141 (40) 141 (13) 141 (6) 141 (4) 141 (6) 141 (6) 141 (4) 141 (38) 141 (72) 141 (7) 141 (5)
Steroid glucuronide
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Table 11. Negative ion mode ESI-MS/MS; m/z (rel. abundance), n.d. = not detected. See Table 3 for structures and nomenclature. Collision offset voltage 40 V. 
The table continues in the next page. 
 
Ions 3-OHSTG 5α-1-MEG 5α-AG   5α-DHTG 5α-DROSTG 5α-MEG 5α-MESM1G 5α-MESM2G 5α-MTG 5α-NG  5β-BOLDG 5β-EPIMG 5β-MTG   
Precursor
[M-H]- 519 (1) 477 (14) 467 (26) 465 (22) 479 (62) 477 (56) 479 (100) 481 (81) 481 (89) 451 (52) 463 (16) 479 (100) 481 (100)
Product ions
[M-H-H2O]
- n.d. 459 (1) 449 (1) 447 (2) 461 (2) 459 (7) 461 (4) 463 (4) 463 (6) 433 (5) 445 (1) 461 (8) 463 (6)
[M-H-Glu]- 343 (41) 301 (26) 291 (6) 289 (3) n.d. 301 (5) 303 (1) 305 (1) 305 (1) n.d. 287 (4) 303 (9) n.d.
[M-H-Glu-2H]- n.d. 299 (22) 289 (11) 287 (2) 301 (4) n.d. 301 (3) 303 (1) 303 (1) 273 (12) 285 (5) 301 (1) 303 (4)
[Glu-H]- 175 (16) 175 (2) 175 (2) 175 (2) 175 (4) 175 (4) 175 (3) 175 (6) 175 (28) 175 (2) 175 (1) 175 (6) 175 (15)
[Glu-H-H2O]
- 157 (2) 157 (5) 157 (6) 157 (5) 157 (6) 157 (11) 157 (15) 157 (15) 157 (36) 157 (11) 157 (3) 157 (9) 157 (18)
[Glu-H-H2O-CO]
- 129 (5) 129 (6) 129 (6) 129 (8) 129 (7) 129 (5) 129 (8) 129 (10) 129 (16) n.d. 129 (4) 129 (9) 129 (9)
m/z 113 (100) (55) (47) (51) (100) (100) (87) (88) (90) (75) (100) (57) (59)
m/z 99 (11) (9) (5) (7) (5) (5) (2) (5) (4) (6) (6) (9) (4)
m/z 97 n.d. (4) (4) (4) (1) n.d. (1) (2) (1) (1) (5) (4) (1)
m/z 95 (7) (15) (18) (15) (9) (8) (13) (10) (10) (12) (9) (8) (6)
m/z 85 (19) (100) (100) (100) (95) (55) (96) (100) (100) (100) (89) (61) (41)
m/z 75 (6) (70) (60) (88) (71) (85) (100) (98) (89) (82) (82) (40) (49)
m/z 59 (6) (7) (6) (5) (11) (18) (3) (7) (12) (6) (6) (4) (3)
Steroid glucuronide
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Table11. See the previous page for the title of the table. 
Ions 5β-NG   7α-BOLAG 7β-CALUG AG        ETCG   ETG       MTG       NG        TG         5β-LMTG d4-AG    d3-5α-DHTG d3-ETG  d3-TG    
Precursor
[M-H]- 451 (57) 495 (100) 495 (100) 465 (59) 465 (35) 463 (11) 477 (15) 449 (11) 463 (18) 484 (95) 469 (33) 468 (23) 466 (14) 466 (10)
Product ions
[M-H-H2O]
- 433 (3) 477 (3) 477 (4) 447 (4) 447 (2) 445 (1) 459 (2) 431 (1) 445 (1) 466 (7) 451 (1) 450 (1) 448 (1) n.d.
[M-H-Glu]- n.d. 319 (1) 319 (1) 289 (6) 289 (1) 287 (6) 301 (15) 273 (32) 287 (22) n.d. 293 (2) 292 (2) 290 (6) 290 (6)
[M-H-Glu-2H]- 273 (3) 317 (1) 317 (1) 287 (8) 287 (1) 285 (6) n.d. 271 (23) 285 (15) 306 (14) 291 (2) 290 (1) n.d. n.d.
[M-H-Glu-2D]- n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 286 (1) 286 (3)
[Glu-H]- n.d. 175 (4) 175 (5) 175 (13) 175 (4) 175 (4) 175 (2) 175 (4) 175 (9) 175 (28) 175 (6) 175 (4) 175 (5) 175 (3)
[Glu-H-H2O]
- 157 (9) 157 (3) 157 (9) 157 (25) 157 (12) 157 (9) 157 (4) 157 (9) 157 (14) 157 (21) 157 (9) 157 (6) 157 (8) 157 (6)
[Glu-H-H2O-CO]
- 129 (6) 129 (6) 129 (5) 129 (16) 129 (8) 129 (7) 129 (5) 129 (6) 129 (10) 129 (10) 129 (10) 129 (8) 129 (6) 129 (5)
m/z 113 (55) (11) (58) (100) (82) (100) (48) (75) (92) (81) (86) (72) (89) (82)
m/z 99 (6) (2) (5) (7) (6) (9) (9) (8) (8) (17) (8) (7) (10) (3)
m/z 97 n.d. (1) (1) (2) n.d. (1) n.d. (4) (5) n.d. (1) n.d. n.d. n.d.
m/z 95 (7) (4) (8) (12) (11) (12) (12) (11) (11) (21) (14) (14) (14) (11)
m/z 85 (100) (27) (54) (97) (100) (97) (100) (100) (100) (86) (100) (100) (100) (100)
m/z 75 (82) (31) (51) (95) (86) (90) (63) (77) (80) (100) (95) (78) (95) (72)
m/z 59 (5) (2) (3) (7) (6) (9) (6) (6) (6) (12) (6) (7) (7) (5)
Steroid glucuronide
 47 
 
The precursor ion [M-H]- was more stabile in negative ion ESI than the precursor ion in 
positive ion ESI, because the carboxylic acid group of the glucuronide moiety delocalizes the 
negative charge. In the comparison of AAS glucuronides, it also became apparent that [M-H]- 
ions of 3-O-glucuronides are more stabile than those of 17-O-glucuronides (Table 11). The 
lesser stability can be explained by the additional strain caused by the methyl substitution at 
C-18. As in positive ion MS/MS, the purpose of collision offset voltage optimization was to 
find suitable conditions for the formation of structure-specific product ions. In negative ion 
mode these ions were those produced after cleavage of the glucuronide moiety [M-H-Glu]-, 
after the abstraction of two additional hydrogens [M-H-Glu-2H]-, and after the loss of water 
[M-H-Glu-nH2O]-. Collision offsets below 25 V were not sufficient to fragment the stabile 
[M-H]- ion, but as soon as the optimized 40 V was reached, the structure fragmented 
intensively. The most abundant fragments originated from the glucuronide moiety, 
unfortunately, and were identical with those of every other AAS glucuronide (Table 11). The 
characteristic ions were very weak in intensity, and thus, negative ion MS/MS was not 
suitable for the monitoring of trace levels of AAS glucuronides. Despite the inadequate 
structure-specific information on the steroid aglycone, negative ion MS/MS may offer a 
complementary method to positive ion MS/MS and could be employed as a tool, for instance 
in ADME studies, to indicate the presence of glucuronide conjugated drug metabolites. 
 
Both positive and negative ion modes were also investigated with use of atmospheric pressure 
chemical ionization (APCI, III). The APCI process is thermally more energetic than ESI, 
however, which enhances the in-source fragmentation and hence decreases the sensitivity. 
The MS/MS fragmentation by APCI did not offer any information additional to ESI and ESI 
is thus the ionization method of choice for the further LC–MS/MS method development. 
Similarly to APCI, the excess of thermal energy also caused fragmentation in atmospheric 
pressure photoionization (APPI). In preliminary studies where toluene was used as the dopant 
solvent, ionization of TG was observed with both polarities of APPI, but the ionization was 
not as efficient as with ESI. APPI has been successfully applied to the analysis of non-
conjugated AAS in urine (Robb et al., 1999; Leinonen et al., 2002), as well as to the 
identification of glucuronide-conjugated drug metabolites such as apomorphine, dobutamine, 
and entacapone in biological samples (Keski-Hynnilä et al., 2002). In both two cases, 
however, the analytes were ionized most efficiently with ESI. It would be interesting to 
examine the feasibility of APPI for the ionization of AAS glucuronides where normal-phase 
chromatography was applied to the separation of the compounds, because the solvent systems 
might provide ionization of the analytes without the need for additional dopant solvent.      
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5.3.3 Application of LC–ESI-MS/MS to the analysis of AAS glucuronides 
 
In enzyme-kinetic studies, with the relatively simple phosphate buffer matrix, precipitation of 
the proteins and solid-phase extraction (SPE) were sufficient sample preparation steps for the 
removal of the interfering salts and enabled the analysis of AAS glucuronides at low 
concentrations (1–5 ng/ml). Problems arose as soon as the analytes were spiked in urine, 
which contains a wide variety of metabolic end products, including endogenous steroid 
glucuronides (IV). An aspect worth noting, especially in quantitative analysis, is the limited 
dynamic range of ESI. This is relevant in any of the stages of the ionization process, i.e. in the 
formation of charged droplets, in the transfer of ions from liquid to gas phase, and in the 
introduction of sample ions to the mass analyzer (Kostiainen and Bruins, 1994). Each ion 
competes with the others in the ESI process that transfers ions from solution to gas phase, and 
the transfer is dependent on both the concentration and the relative ionization efficiency of the 
species (Kebarle, 2000). Thus, the analyte itself in high concentration, interfering background 
electrolytes, or nonvolatile solutes (e.g. impurities remaining after incomplete sample 
purification) may suppress the signal if these occupy the whole droplet surface or form solid 
precipitates within the droplet (King et al., 2000). When this happens, the analytical result 
will be invalid and often the instrument will be contaminated as well.  
 
A 
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Figure 13. Three-phase solvent system of the liquid-phase microextraction (LPME) device: sample 
(S), organic layer (O), and acceptor phase (A). 
 
 
With the traditional liquid–liquid extraction (LLE) and SPE methods, the sample purification 
was insufficient and non-specific, producing high background interference in MRM ion 
traces. Accordingly, after optimization and comparison, a relatively new clean-up technique, 
liquid-phase microextraction (LPME) with hollow polypropylene membrane and three-phase 
solvent system (Figure 13) proved to be the most selective and provided the cleanest extracts. 
Detection limits of 2–20 ng/ml were achieved for most of the 12 AAS glucuronides (IV). 
LPME was initially introduced for the analysis of basic drugs (Pedersen-Bjergaard and 
Rasmussen 1999; Rasmussen et al. 2000; Ho et al. 2002) and anti-inflammatory analgesics 
(Pedersen-Bjergaard and Rasmussen 2000), but here it showed itself suitable for the 
extraction of acidic compounds as well. One explanation for the better specificity obtained 
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with LPME than with LLE or SPE is that the process involves two successive steps in which 
the solvent pH is adjusted. The deionized AAS glucuronides are first dissolved in an organic 
layer and then transferred further to an acceptor phase in ionic form. Although the specificity 
of the method was enhanced with LPME, the recoveries from urine were below 20% for all 
tested AAS glucuronides.  
 
It was of interest to know whether the analytes remain in the sample solution or whether they 
are trapped into the organic layer and, in test of this, the distribution of the analytes among 
sample solution (S), organic solvents (O), and acceptor phase (A) was examined with LLE 
experiments with spiked samples and two phases at a time (S/O, O/A) (Figure 14). In the O/A 
experiment, with any of the organic solvents (n-octanol, octanone, or pentylacetate), the 
analytes were clearly transferred to the acceptor phase side. From this it may be concluded 
that trapping to the organic layer is not the explanation for the relatively low yields in LPME. 
In the S/O experiment, n-octanol extracted the AAS glucuronides most efficiently, showing 
that the initial step, the dissolution of the analyte from the sample solution to the organic 
phase, is the most critical step in LPME. The significance of the selection of organic solvent 
was supported by the experimental results for the complete LPME process, in which the only 
acceptable system relied on the use of n-octanol as the organic phase (IV).           
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Figure 14. An example of the LPME distribution studies with 3-OHSTG. Sample (S), organic layer 
(O), and acceptor phase (A).  
 
 
Despite the results achieved with LPME, the LC–ESI-MS/MS method for urine samples is 
still in need of development, as the background of endogenous compounds interferes with the 
detection of some of the AAS glucuronides. Although a pool of several female and male urine 
samples was used in the method development, differences between the matrix effects of 
individual samples can be expected (Matuszewski et al., 1998). With respect to unsolved 
problems of specificity, sample preparation and chromatographic separation are the critical 
issues in the future method development. 
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6. SUMMARY AND CONCLUSIONS 
 
Glucuronide-conjugated anabolic androgenic steroids (AAS) in milligram amount were 
produced by in vitro enzyme-assisted synthesis. Induced rat liver microsomes were used as 
the source of the conjugating uridine diphosphoglucuronosyltransferase enzymes (UGTs). 
Enzyme-assisted synthesis provided stereochemically pure AAS glucuronide conjugates, 
which makes this method superior to chemical synthesis, where racemic mixtures of α/β-
anomers of the product and undesired by-products are often encountered.  The yields of the 
syntheses were mostly 13–28%, though for substrates with conjugated double bond system 4-
ene-3-one, they were at the significantly higher level of 77–78%. Because the composition of 
the reaction mixture was relatively simple, and the differences in the optimal conditions for 
the various substrates were relatively minor, the addition of a new AAS substrate to the test 
compound set should be straightforward.  
 
Enzyme-assisted synthesis offers a practical pathway for the rapid production of small 
amounts of AAS glucuronides, such as needed in the build-up of an analytical method. Liver 
microsomal preparations should be used in the syntheses, rather than recombinant UGT 
isoenzymes, owing to their higher activity and tolerance against solvents and pH effects of the 
reaction mixture. UGT isoenzymes are nevertheless of unique importance in detailed 
examination of the glucuronidation reaction, for instance, in the screening of the metabolic 
pathways of drugs and drug candidates. For the synthesis of AAS glucuronides in greater than 
low milligram amounts, chemical synthesis is still the method of choice.  
 
Regio- and stereoselectivity of glucuronidation was examined with 11 human recombinant 
UGTs toward 11 steroid substrates. The selected UGTs included members of the UGT1A and 
2B subfamilies, and the substrates were either parent AAS or their phase-I modified 
metabolites with 3α-, 17α-, and/or 17β-hydroxyl groups as the potential sites for O-
glucuronidation. Most UGTs did not exhibit clear preference for conjugation to the 3α-
hydroxyl or the 17β-hydroxyl group; the isoenzymes showing evidence of regioselectivity 
were UGT1A8, 1A9, and 2B15, which appeared to preferentially catalyze 17β-hydroxyl 
glucuronidation. Formation of nandrolone metabolite 5β-NG was favored over the 
corresponding 5α-isomer, 5α-NG, with most of the UGT isoenzymes (UGT1A1, 1A3, 1A4, 
1A10, and 2B4), but the similar stereoselectivity was not detected in the formation of 5α-
MTG and 5β-MTG. 
  
The highly homologous isoforms UGT1A8, 1A9, and 1A10 were similarly active toward the 
planar steroid substrates with 17β-hydroxyl group, whereas the fourth member of that enzyme 
group, UGT1A7, did not exhibit activity toward any substrate. The substrate specificities of 
the two structurally analogous isoenzymes UGT1A3 and 1A4 were also closely similar. Inter-
individual differences were observed in the relative activities among both groups of enzymes, 
however. The main difference between the three types of enzyme preparations studied; 
recombinant UGTs, human liver UGTs, and rat liver UGTs, was detected in the conjugation 
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of methyltestosterone, which was glucuronidated only with the human and rat liver 
microsomal UGTs, the activity of the induced rat liver UGTs being significantly higher than 
those of the human liver preparation. Glucuronidation patterns of the hepatic isoenzymes 
UGT1A3, 1A4, 2B4, and 2B7 generally resembled those of human liver microsomes, which 
indicates that in future, an appropriate selection of UGT isoenzymes might be used as in vitro 
model to predict the glucuronidation reactions of a particular xenobiotic in the human body.  
 
ESI was indicated as the method of choice for ionization of the AAS glucuronides, because 
the excess thermal energy in APCI and APPI decreased the sensitivity. Although both 
polarities were applicable in ESI, positive ion mode MS/MS was selected on the basis of the 
structure-specific fragmentation. Because of the relatively low proton affinities of AAS 
glucuronides, the precursor ion of the MRM pair was most often the ammonium adduct of the 
molecule [M+NH4]+, whereas the product ions originated from the loss of glucuronide moiety 
[M+H-Glu]+ with additional loss of water [M+H-Glu-nH2O]+. From the differences between 
fragment ion ratios, it was also possible to distinguish between some isobaric AAS 
glucuronides with similar product ion spectra.  
 
The optimized LC–ESI-MS/MS method enabled direct analysis of the glucuronide 
conjugates, in which an end-capped C18 column and ammonium acetate buffered acetonitrile–
water gradient were employed for chromatographic separation. Two structure-specific product 
ions, for both the analyte and the deuterium-labeled internal standard, were monitored in 
positive ion ESI-MS/MS. Combined with LLE, LPME, or SPE sample preparation, LC–ESI-
MS/MS was successfully applied in the detection of AAS glucuronides in moderately simple 
matrixes such as those of in vitro metabolic studies. Nevertheless, the high background signal 
of the matrix interfered with the analysis of AAS glucuronides in urine, especially in the 
determination of the methyltestosterone metabolites 5α-MTG and 5β-MTG. The main goal in 
further method development will be the improvement of specificity, which most likely will be 
achieved through further development of the chromatographic separation. In this study, both 
the sample preparation and the chromatographic separation were based mainly on C18 
reversed-phase systems, i.e. non-polar interactions between the analyte and the sorbent or LC 
column. The switch to normal-phase chromatography would likely be difficult for ESI, as the 
solvents do not adequately support ion formation (Voyksner, 1997). Testing of normal-phase 
or ion-exchange based procedures for sample preparation could be a fruitful direction in 
which to proceed.  
 
The real problem, however, is the abundance of endogenous steroid glucuronides, which are 
difficult to remove from samples because of their closely similar structures. In this respect, 
other avenues to explore for improved sample preparation are immunoaffinity 
chromatography (IAC), based, for example, on the specific 17α-methyl-17β-hydroxy-
structure of synthetic AAS aglycones, and the use of multi-analyte antibodies (Crooks et al., 
1997). The alternative approach, modification of the chromatographic separation, would 
involve the testing of normal-phase LC-columns and solvent systems. With this combination 
the suitability of APPI for the ionization method should be examined. The use of more 
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specific techniques, such as immunoaffinity and chiral separation, could enhance the 
specificity of the method. The number of viable alternatives appears fewer in the MS 
detection. The fragmentation of the different AAS glucuronides is fairly similar, and the 
selection of structure-specific target ions is limited. Experiments with different scan modes 
(neutral loss and precursor ion scan) did not offer any additional data to the product ion scan 
of MRM either. The detection limits were nevertheless low when pure standards were 
measured in pure solvents, so the main focus of the method development should be on sample 
preparation and chromatographic separation.  
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